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SYNOPSIS
1The research work incorporated in the thesis with entitled “STUDIES ON
SOME HETEROCYCLIC COMPOUNDS OF THERAPEUTIC INTEREST”
has been described as under.
These valid observations prompted us to design and synthesize some
heterocycles like chalcones, pyrazolines, cynopyridines, pyrimidines, isoxazoles,
Barbitones, Mannich bases, Schiff’s base etc., bearing imidazo [1,2-a] pyridine ring.
PART – I : STUDIES ON CHALCONES
Chalcones are phenylstyrylketones containing reactive keto- ethylenic group.
Literature survey reveals that chalcone derivatives possess antibacterial, antiviral,
antispasmodic activities. Hence it was thougth worth while to synthesize chalcone
derivatives, which have been described as under.










The Chalcones of Type - (I) have been synthesized by the condensation
of 2-(4-chlorophenyl)-6-methylimidazo [1, 2-a] pyridine-3-carboxaldehyde with
aromatic ketones in the presence of aqueous NaOH.
PART-II : STUDIES ON PYRAZOLINES
Pyrazoline derivatives are one of the most active therapeutic activity such as
antibacterial, analgesic, anthelminetic, anti-inflammatory, anti-tubercular etc. This
valid observation led us to sythesize some new pyrazoline derivatives, which have
been described as under.
2SECTION-I : Synthesis and biological Screening of 2 - ( 4' - chlorophenyl)-6-








Pyrazoline derivatives of Type- (II) have been synthesized by the
condensation of chalcones of Type -(I) with hydrazine hydrate.
SECTION-II : Synthesis and biological Screening of 2-(4'-chlorophenyl)-6-
Methyl-3-(3"-aryl -1"acetyl-4", 5"-dihydropyrazol-5"-yl)










Acetyl pyrazoline derivatives of Type (III) have been synthesized by the
condensation of chalcones of Type- (I) with hydrazine hydrate and glacial acetic acid.










Phenyl pyrazoline derivatives of Type (IV) have been synthesized by the
condensation of chalcones of Type- (I) with phenyl hydrazine.
PART - III : STUDIES ON CYANOPYRANS
Cyanopyran derivatives represents one of the modest classes of the
compounds possessing wide range of therapeutic activities such as antibecterial,
antifungal, antiviral and anticonvulsant etc. In view of these facts, it was
contemplated to sythesized some new Cyanopyrans, which have been described as
under.
SECTION-I : Synthesis and biological Screening of 2" – amino - 4" - [ 2 - ( 4'-











4Cyanopyran derivatives of Type-(V) have been synthesized by the
Condensation of chalcones of Type- (I) with malononitrile in pyridine.
PART-IV : STUDIES ON CYANOPYRIDINES
Cyanopyridines nucleus possess remarkable pharmaceutical importance and
biological activities. Cyanopyridine derivatives have been reported to be active as
antifungal, antidiabetic, anticholestemic and antihypertensive etc. On the basis of
these results, prompted us to synthesize some new cyanopyridines derivatives, which
have been described as under.
SECTION-I : Synthesis and biological Screening of 2"-methoxy - 4"- [ 2 - ( 4'-











Cyanopyridine derivatives of Type- (VI) have been synthesized by the
Condensation of chalcones of Type- (I) with malononitrile and sodium methoxide.
SECTION-Il : Synthesis and biological Screening of 2"-amino-4"-[2-(4'-










5Cyanopyridine derivatives of Type -(VIl) have been synthesized by the
condensation of chalcones of Type- (I) with malononitrile and ammonium acetate.
PART-V : STUDIES ON PYRIMIDINES
Pyrimidine nucleus possess remarkable pharmaceutical importance and
biological activities, some of their derivatives occur as natural products, like nucleic
acids and vitamin B. Many pyrimidine derivatives have displayed diverse
pharmacological activities like antitumor, antibacterial, antimalarial, antifungal etc.
These valid observations prompted us to synthesize some new substituted
pyrimidines, which have been described as under.
SECTION-I : Synthesis and biological Screening of 4"-[2-(4'-chlorophenyl)-6-










Aminopyrimidine derivatives of Type- (VIII) have been synthesized by the
condensation of chalcone of Type- (I) with guanidine hydrochloride.
SECTION-II : Synthesis and biological Screening of 6"-[2-(4'-chlorophenyl)-6-










6Pyrimidinone derivatives of Type-(IX) have been synthesized by the
cyclization of chalcones of Type- (I) with urea in presence of basic catalyst KOH.
SECTION-III: Synthesis and biological Screening of 6"-[2-(4'-chlorophenyl)-6-










Thio Pyrimidine derivatives of Type-(X) have been synthesized by the
cyclocondensation of chalcones of Type - (I) with thiourea in presence of basic
catalyst KOH.
PART-VI : STUDIES ON ISOXAZOLES
Isoxazole derivatives represent one of the modest class of compound
possessing broad range of biological activities such as antidepresants, skeleton muscle
relaxant, antidiabetic, anti-inflammatory, analgesic, antimicrobial etc. These valid
observations prompted us to synthesize some new isoxazole derivatives described as
under.
SECTION-I : Synthesis and biological Screening of 2-(4'-chlorophenyl)-6-








7Isoxazole derivatives of Type-(XI) have been synthesized by the
cyclocondesation of chalcones of Type- (I) with hydroxylamine hydrochloride.
PART-VII : STUDIES ON BARBITONES
Barbitone derivatives have been found to biological activities viz.
anticonvulsant, hypnotic, sedatives, anti-inflammatory etc. Promoted by above facts,
some new barbitones have been synthesized as under.














The barbitone derivatives of Type- (XII) have been synthesised by the
condensation of chalcone of Type- (I) with barbituric acid in glacial acetic acid.
PART – VIII : STUDIES ON 5-OXO-IMIDAZOLINES
5–Oxo-imidazoline derivatives have been reported to be active as
anticonvulsant, potent CNS depressant, anti-inflammatory, anticancer, hypnotics and
as mono aminooxidase (MAO) inhibitor.These valid observations prompted us to
synthesize some new 5-oxo-imidazoline derivatives. which have been described as
under.
8SECTION-I: Synthesis and biological Screening of 2-[(4'-chlorophenyl)-6-methyl









5-Oxo-imidazoline of Type- (XIII) have been synthesized by the
condensation of 4"-{[2-(4'-chlorophenyl)-6-methyl imidazo [1,2-a] pyridin-3-yl]
methylene}-2"-phenyl- 5"-oxazolone with aromatic amine.
PART – IX : STUDIES ON MANNICH BASES
Mannich bases containing bridge N-atom exhibit diverse pharmacological
activities like antibacterial, antimalarial, antineoplastic, analgesic, anticonvulsant etc.
Mannich bases are also found as intermediate in organic synthesis and good chelating
agent hence it is pertinent to synthesize new mannich base, which have been
described as under.
SECTION-I : Synthesis and biological Screening of 2-(4'-chlorophenyl)-6-








9Mannich bases of Type- (XIV) have been synthesized by the
condensation of 2-(4'-chlorophenyl)-6-methyl imidazo [1, 2-a] pyridine with
different secondary amines and formaldehyde in the presence of acidic catalyst like
HCl.
PART – X : STUDIES ON SCHIFF'S BASES
Arylaminomethyl derivatives represent one of the modest class of biological
active agent which have been deeply studies during search on new potential agent.
These have been reported to be active as antimicrobial, antitubercular, anticancer and
insecticidal etc. In view of these valid observation, it was contemplated to synthesize
some new schiff’s base derivatives possessing wide biological activities which have
been described as under.
SECTION-I : Synthesis and biological Screening of 2-[(4'-chlorophenyl)-6-







Schiff’s base of Type - (XV) have been synthesized by the condensation
of 2 -(4'-chlorophenyl)-6-methylimidazo [1, 2-a] pyridine-3-carboxaldehyde with
aromatic amine.
ART – XI : STUDIES ON BENZODIAZEPINES.
Benzodiazepines derivatives have been found to possess wide range of
therapeutic activities, like anthelmintic ,anticonvulsant, antimicrobial etc. Prompted
by these facts new Benzodiazepines have been synthesize which are described as
under.
10
SECTION-I : Synthesis and biological Screening of-4"-aryl-2"-yl-[2-(4'-










Bnzodiazepines derivatives of Type- (XVI) have been synthesized by the
reaction of chalcones of Type -(I) with o-phenylene diamine in presence of acidic
medium.
Characterization:
The constitution of the synthesized products have been characterized using
elemental analysis, IR and 1H NMR and further supported by mass spectra. Purity of
the all compounds have been checked by thin layer chromatography.
Studies on biological activities.
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
toward at a concentration of 50 µg/ml. The biological activity of the sythesized







The chemistry of therapeutic interested compound had it’s beginning when
chemists, pharmacists and physicians isolated purified active principles of plant and
animal tissues and later from micro organisms and their fermentation products. some
of this chemicals had been associated with therapeutic properties is often ill-defined
disease condition.
The focus of drug design has switched from structure oriented to target
oriented research, e.g. development of the antiulcer agent cimetidine. histamine was
the lead compound for the project and various strategies were used to find an analog
that would prevent it fitting its receptor. once an antagonist was developed, a theory
was proposed on how it might interact with the histamine receptor at a molecular
level. further analogs were then synthesized to test theory and the theory was
continuously modified as required.
Modern drug discovery starts with the identification of a pharmacologic target
that is hypothetically the primary cause of disease. Potential targets include host cell
genes, receptors, signaling systems, organelles and biochemicals such as enzymes.
Additionally, an element of a disease modifying process, such as anti-inflammatory
mediator, may be a target. Biological processes required for propagation of infectious
agents have also proven to be therapeutically useful targets; examples include
protease and reverse transcriptase of the human immuno deficiency virus (HIV).
Common to all targets selected as therapeutic opportunities is the hypothesis that
some type of pathogenetic linkage exists to the disease causing process, rather than to
specific signs, symptoms, or effects.
Heterocyclic compounds have great applicability in pharmaceutics because
they have specific chemical reactivity and provide false synthons in biosynthetic
process or block the normal functioning of biological receptors. The inhibition of
amide resonance resulting into more susceptibility of β-lactam to nucleophile is
considered at least in part responsible for antibacterial property, apparently by
acetylating transpeptidase and thus inhibiting bacterial cell wall biosynthesis.
Most of the alkaloids which are nitrogenous bases occurring in plants and
many antibiotics including penicillin and streptomycin have also heterocyclic ring
system. Many natural pigments such as indigo, haemoglobin and anthocyanin are
heterocycles. Most of the sugars are their derivatives including Vitamin C for
13
instance, exist largely in the form of five membered. Vitamin B6 (Pyridoxine) is a
derivative of pyrimidine essential in amino acid metabolism.
Important drugs, poisons and medicines (both natural and synthetic) such as
sulphathiazole, pyrenthrin, rotenmone, alpidem, zolpidem, fluconazole, strychnine,
reserpine, certain of the antihistamines, the ergot alkaloids caffeine, cocaine,
barbiturates, etc. are heterocyclic compounds.
The word ‘drug’ is derived from the French word ‘drogue’ which means a dry
herb. According to “WHO” a drug may be defined as “any substance or product
which is used or intended to be used for modifying or exploring physiological
system or pathological status for the benefit of recipient”.
The ultimate product of a successful drug design effort. Our goal for this is to
begin to deconvolute this information in order to apply it to design of new drugs.
Taking in view of the applicability of heterocyclic compounds, we have undertaken
the preparation of heterocycles bearing imidazo[1,2-a]pyridine nucleus. The
placement of a wide variety of substituents of these nuclei has been designed in order
to evaluate the synthesized products for their pharmacological profile against several
strains of bacteria and fungi.
The ultimate product of a successful drug design effort. Our goal for this is to
begin to deconvolute this information in order to apply it to design of new drugs.
Taking in view of the applicability of heterocyclic compounds, we have
undertaken the preparation of heterocycles bearing imidazo[1,2-a]pyridine nucleus
The placement of a wide variety of substituents of these nuclei have been designed in
order to evaluate the synthesized products for their pharmacological profile against
several strains
Of becteria and fungi.
AIMS AND OBJECTIVES
In the pharmaceutical field, there is a need for new and novel chemical
inhibitors of biological functions. Our efforts are focused on the introduction of
chemical diversity in the molecular frame work in order to synthesizing
pharmacologically interesting heter ocyclic compounds of widely different
composition. During the course of research work looking to the applications of
heterocyclic compounds, several entities have been designed, generated and
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characterized using spectral studies. The aims and objectives of the work carried out
are as under.
1. To synthesize pharmacologically active entities like chalcones,
cyanopyridines, pyrazolines, schiffbases, cynopyrans, isoxazoles,
Mannichbases, Barbitones,Pyrimidines,Benzodiazipines, cyanopyrimidines,
5-Oxo-imidazolines etc.
2. To characterise these products for structural elucidation using spectroscopic
techniques like IR,1 HNMR and Mass spectral studies .
3. To check the purity of all compounds using thin layer chromatography.
4. To evaluate these new products for better drug potential against different
strains of bacteria and fungi.
In a programmed research directed towards the construction of therapeutically
active new heterocycles bearing Imidazo[1,2-a] pyridine nucleus has been







Bridge nitrogen containing fused heterocycles represents important building
blocks in both natural and synthetic bioactive compounds which have been shown to
possess diverse therapeutic activities1. Hence they are interesting target to be prepared
to our research on medicinally interesting heterocyclic entities. Aza-indolizine are of













The aza-indolizine contains a pyridine ring fused to a imidazole ring is
indicated in the structure, hence it is also known as imidazo[1,2-a]pyridine2. Many
drugs contain imidazo[1,2-a] nucleus. Several procedure for their synthesis have been
extensively studied. Such studies have been stimulated by various promising
applications, especially in the case of bridge head nitrogen containing fused
heterocyclic entities.
The constitution of imidazo[1,2-a]pyridine was represented by W. L.Mosby3.
Imidazo[1,2-a]pyridine derivatives not only known for their medicinal applications,
but they are also used in disperse dye4.
SYNTHETIC ASPECT:
Classical methods have been reported in the literature for the synthesis of
imidazo[1,2-a]pyridines. The procedure for synthesizing imidazo[1,2-a]pyridines
have been described as under.
1. The synthesis of imidazo[1,2-a]pyridine from 2-aminopyridine with
α-bromoacetophenone was reported by Tschitschibabine5.
2. Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent elimination








3 2-Acetylimidazo[1,2-a]pyridine7 can be constructed by the cyclocodensation






4. Condensation of ethyl-6-aminonicotinate with chloroacetaldehyde according













5. Paudler et al.9 have synthesized 5-amino-3-formylimidazo[1,2-a]pyridine from
















6 Imidazo[1,2-a]pyridine10 nucleus can be also synthesized by the reaction of












7. Tsai et al.11 have been prepared 3-amino imidazo[1,2-a]pyridine derivatives by
a three component condensation reaction between 2-aminopyridine, aldehyde














8. Groziak et al.12 have synthesized substituted imidazo[1,2-a]pyridine
derivatives by the condensation of 2-aminopyridine with glyoxal trimer















The majority of imidazo[1,2-a]pyridine have been synthesized by 2-amino

















R, R1, R2 = Aryl, X = Hal
THERAPEUTIC IMPORTANCE
Imidazo[1,2-a]pyridines are potential bioactive agents due to their wide
spectrum of therapeutic importance. A large number of substituted imidazo[1,2-
a]pyridine derivatives are prepared and tested for varieties of biological activities such
as,











11. Hypnoselective and anxioselective29
12. b-Amyloid formation inhibitors30
13. Benzodiazepine receptor agonists31
14. Nonsedative anxiolytic32
15. Active nonpeptide bradykinin B2 receptor antagonists33
16. Cardiotonic agents34
17. Anticytomegalo-zoster and antivaricellazoster virus35-37
18. Long-acting local anesthetic38
19. Calcium channel blockers39
Some imidazo[1,2-a]pyridines already in market include alpidem40 (III)[a
ligand of both the central benzodiazepine receptors and the peripheral type
benzodiazepine receptor] has sedative and anxiolytic properties and zolpidem40(IV)
[a selective ligand for the central benzodiazepine receptor] is a hypnotic drug.
Bothalpidem and zolpidem have higher affinity for enzodiazpine-1 than for




































J. J. Kaminski and co-workers43 have investigated the imidazo[1,2-a]pyridine
derivative 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine (V)
as an antiulcer agent. On the basis of the reported metabolism of zolimidine(VI), they











(VI) ZolimidineI li i i
Pharmaceutical research requires an increasing number of novel compounds to
cover previously unexplored areas in the chemical space. there is also a need to
increase the quality of the newly prepared molecules regarding their drug likeness and
other predefined physicochemical parameters. C. Alexander. Humphries and co-








































Evaluated as a bioisosteric replacement for imidazo[1,2-a]pyridine in an
allosteric modulator ligand of the GABAA receptor. Kristian S. Gudmundsson44 have
reported the synthesis and antiviral activities of newer Erythrofuranosyl imidazo[1,2-
a]pyridine C-nucleosides. I. Aramori et al.45 have been synthesized highly potent and
selective non-peptide bradykinin receptor antagonist (VIII).A Novel Class of Orally
Active Non-Peptide Bradykinin B2 Receptor Antagonist and Discovering
Bioisosteres of the Imidazo[1,2-a]pyridine Moiety reported by Yoshito
Abe.46Synthesis of Acyclo-C-nucleosides in the
Imidazo[1,2-a]pyridine and Pyrimidine Series as Antiviral Agents.47 Dubinsky B and
A.H.Vaidya.48 has defined like imidazo [1,2-a] pyridine deri. is a new
nonbenzodiazepine anxiolytic.
The imidazo[1,2-a]pyridine bearing a very good synthon variety of
building blocks in both natural and synthetic bioactive compounds.49-51 Mohamed A.
Ismail 53 have recently synthesized some novel diamidine imidazo[1,2-a]pyridine
like (IX) and (X) and 5,6,7,8-tetrahydo imidazo[1,2-a]pyridines and their
corresponding N-hydroxy and N-methoxy analogues which are potential for this
series and their evaluation versus trypanosoma b. rhodesiense and plasmodium
falciparum. More ever synthesise Aromatic diamidines exhibit broad spectrum
antimicrobial activity including effectiveness against the protozoa disease caused
by trypanosoma SP and plasmodium SP. Novel substituted imidazo [1,2-a] pyridine
compounds are disclosed which have a high degree of anthelmintic activity. Processes
for the preparation of such compounds are also disclosed as well as active ingredients
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a - R: H;pera connection









a - R: H;pera connection
b - R: H;meta connection
(X)
Kristjan S., Gudmundsson, Brian Johns A.53and Chaouni Bendallay A. et al.54
have worked on synthesis of a novel imidazo[1,2-a] pyridine shown in (XI) with









Thus the important role displayed by imidazo[1,2-a]pyridine and its derivatives for
various therapeutic and biological activities prompted us to synthesise some
Chalcones, Phenyl pyrazolines, Cyano pyridines, Thiozolidinones, Cyclohexenone,
Schiff’s base, Aryl amino methyl derivatives bearing imidazo[1,2-a]pyridine moiety
in order to active compounds having better biological activities as described in the
following parts.
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STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
PART – I : STUDIES ON CHALCONES
PART- II : STUDIES ON PYRAZOLINES
PART - III : STUDIES ON CYANOPYRANS
PART- IV : STUDIES ON CYANOPYRIDINES
PART- V : STUDIES ON PYRIMIDINES
PART- VI : STUDIES ON ISOXAZOLES
PART- VII : STUDIES ON BARBITONES
PART – VIII : STUDIES ON 5-OXO-IMIDAZOLINES
PART – IX : STUDIES ON MANNICH BASES
PART – X : STUDIES ON SCHIFF BASES










The chemistry of chalcones have generated intensive scientific studies
throughout the world, specially interesting for their biological and industrial
applications. Chalcones are coloured compounds because of the presence of the
chromophore and auxochromes. They are known as benzalacetophenones or
benzylidene acetophenones. Kostanecki and Tambor55 gave the name Chalcone.
Chalcones are characterized by their possession of a structure in which two
aromatic rings A and B are linked by an aliphatic three carbon chain.
The alternative names given to chalcones are phenyl styryl ketones,
beanzalacetophenone, β-phenyl acrylphenone, γ-oxo-α-γ-diphenyl-α-propylene and α-
phenyl-β-benzoethylene.
SYNTHETIC ASPECT :
A variety of methods are available for the synthesis of chalcones. The most
convenient method is the one that involves the Claisen-Schmidt condensation of
equimolar quantities of a aryl methyl ketones with aryl aldehyde in the presence of
alcoholic alkali.56, 57 Various condensing agent used for the synthesis of chalcones are
alkali of different strength.58-59 Hydrogen chloride60-61 Phosphorous oxychloride62,
Piperidine63, Anhydrous AluminiumChloride64, Borontrifluoride65, Borax66,
Aminoacids67, Perchloricacid68 etc.
MECHANISM
The following mechanisms have been suggested for the synthesis of chalcone.
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Carbanion formation observes in presence of alkali media and the intermediate aldol
type products formed readily undergoes dehydration even under mild condition and
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The chalcones have been found to be useful for the synthesis of many
heterocyclic compounds.
1. Chalcones are intermediate compounds for the synthesis of some naturally occuring
heterocyclic compounds like flavones, flavanones, flavanoid, dihydro flavanols,
benzal coumarinones, anthocyanins etc.
2. Chalcone contain a keto-ethylenic group and therefore reactive towards number of
reagents yielding various heterocyclic compounds exhibiting significant biological
activities viz. pyrazolines69, cyanopyridines70, cyanopyrans71, cyanopyridones72,
pyrimidines73-75, isoxazoles76, indazole77 etc.
3. They have been useful in providing structure of some natural products like
cyanomulcurin78, eviodictoyl79, hemlocktanin80, narighenin81, plioretin82 etc.
4. Chalcones are also useful for the detection of Fe (II) 83 and Ca (II) 84 ions in
presence of Barium and Stronsium as it reacts with number of metal ions.
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Trihydroxy chalcones was used as an analytical reagent for amperometric
estimation of Copper85 and for spectrophotomatric study of the Germanium 86.
5. Chalcones and their derivatives are also found to be applicable as light Chalcone
and their derivatives are also found to be applicable as light stabilizing agent87,
sweetening agent88, organic brightening agent, photo sensitive material,
polymerisation catalyst, scintillators as well as fluorescent whitening agent.
6. The chalcones are natural biocides89, 90 and are well-known key intermidiate in the
synthesis of heterocyclic compounds possessing biodynamic behaviour 91-92.
THERAPEUTIC INTEREST :
Chalcones derivatives have been found to possess wide range of therapeutic















Chalcones are potential biocides, because some naturally occurring
antibiotics117 and aminochalcones118, 119 probably own their biological activity in the
presence of the α, β-unsaturated carbonyl group. G. L. Nelson120 has synthesized the
analogues of prostaglandin (II).
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Prem P. Yadav and co-workers121 have synthesized nitrogen and sulfur
containing furanoflavonoids and thiophenylflavonoids (III), Which have been
screened fo antifungal and antibacterial activity. C. Q. Meng et al.122 discovered
some novel heteroaryl substituted chalcones (IV) as inhibitors of TNF-alpha-induced
VCAM-1 expression.
Some dihydrochalcones are well known for their sweetening property123, 124
and appear to be non-nutritive sweeteners. A dihydrochalcone Uvaretin from Uvaria
acuminata has shown antitumor activity125 in lymphocytic leukemia test.
V.K. Ahluwalia et al.126 have noted that 5-cinnamoylchalcones (V) have
shown good as antibacterial activity.
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Paula Boeck et al.127 have synthesized novel chalcone analougs (VI) with
antileishmanial activity. Analougs containing nitro, fluorine or bromine group
respectively displayed increased selectivity against the parasites as compared with
natural chalcone.
Furthermore, M. J. Alcaraz et al.128 have described the role of nuclear factor-
kappaB and heme oxygenase-1 in the mechanism of action of an antiinflammatory
activity of chalcone derivative. O. Nerya et al.129 have prepared chalcones as potent
tyrosinase inhibitors. O. Sabzevari et al.130 have constructed some new chalcone
derivatives (VII) as molecular cytotoxic mechanisms for anticancer activity. Aneta
Modzelewska et al.131 have prepared novel chalcone and bis chalcone derivatives
(VIII) having anticancer activity.
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Chalcones have been proved to be an important intermediate for the synthesis
of many heterocyclic compounds in organic chemistry. These facts prompted us to
synthesize some new chalcone derivatives bearing imidazo[1,2-a]pyridine as a
nucleus. In view of getting to synthesised chalcone derivative, Which also wide use
in pharmaceutical field the chalcone derivatives are represented as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-
CHLOROPHENYL)- 6-METHYL- 3-[1"-ARYL- 2"-PROP
ENE-1"ONE-3-YL ]-IMIDAZO[1,2-a]PYRIDINES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL- 3-[1"-ARYL- 2"-PROPENE-1"-ONE-3-YL ]-IMIDAZO[1,2-a]
PYRIDINES.
Recently much interest has been focused on the synthesis and biodynamic
activities of chalcones and it is a good synthon for various heterocyclic rings, the
interest has been focused on the synthesis of new chalcones. With a view to obtained
compounds having better therapeutic activity, we have synthesized 2-(4'-
chlorophenyl)-6-methyl-3-[1"-aryl-2"propene-1"-one-3-yl]-imidazo[1,2-a]pyridine by
the condensation of 2-(4'-chlorophenyl)-6-methylimidazo [1, 2-a] pyridine-3-















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I,page no.41.
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IR SPECTRAL STUDY OF 2 - ( 4' – CHLOROPHENYL )-6-METHYL- 3-[1"-
(4'''-METHYLPHENYL)- 2" – PROPENE - 1" –ONE- 3-YL ]-IMIDAZO [1,2-a]
PYRIDINE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2964 2990-2850 648
C-H str. (sym.) 2860 2880-2860 "
C-H def. (asym.) 1442 1470-1435 "
Alkane
C-H def. (sym.) 1369 1390-1370 "
C-H str. 3057 3090-3030 "
C=C str 1500 1450-1600 "
Aromatic
C-H i.p. (def.) 1138 1300-1100 649
Ketone C=O str. 1680 1700-1640 "
C-N str. 1105 1220-1020 "Imidazo[1,2-a]
pyridine C=N str. 1600 1630-1593 "
Vinyl CH=CH 3003 3050-3000 "
Ether C-O-C 1219 1260-1200 "
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NMR SPECTRAL STUDY OF 2 - ( 4' – CHLOROPHENYL )-6-METHYL- 3-
[1"-(4'''-METHYLPHENYL)- 2"-PROPENE-1"-ONE-3-YL ]-IMIDAZO [1,2-a]
PYRIDINE.








1 2.43 3H singlet Ar-CH3(j)
2 2.44 3H singlet Ar-CH3(k)
3 7.22-7.25 1H doublet Ar-H(f)
4 7.26-7.30 2H doublet Ar-H(aa')
5 7.45-7.49 3H doublet Ar-H(cc',e)
6 7.61-7.64 1H doublet CH=CH(h)
7 7.71-7.74 2H doublet Ar-H(dd')
8 7.81-7.84 2H doublet Ar-H(bb')
9 8.10-8.14 1H doublet Ar-H(i)
10 8.21 1H singlet Ar-H(g')








MASS SPECTRAL STUDY OF 2 - ( 4' – CHLOROPHENYL )-6-METHYL- 3-[1"-(4'''-METHYLPHENYL)- 2"-ROPENE-1"-ON E
-3-YL ]-IMIDAZO [1,2-a] PYRIDINE.





























































































TEA Reflux 4 hrs
CHCl3
Reflux 6 hrs
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL- 3-[1"-ARYL- 2"-PROPENE-1"-ONE-3-YL ]-IMIDAZO [1,2- a]
PYRIDINES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine :
Arranged 1.0 lit 4/N RBF equipped with stirrer tharmopoket and condensor.
Charge 100ml methanol and 21.3g (0.1 mole) (4-chlorophenyl)acetyl chloride and
then charge 11.9g (0.11mole) 2-amino 5- methyl pyridine at room temperature stir
till clear solution. Add drop wise 5.9g (0.055mol) triethylamine at room
temperature till PH adjust 8 to 9. After addition complete heat 60-65 oC for 3 to 4
hrs, then check TLC. After complies TLC cool reaction mass at room temperature
and pour in crused ice filter and dry it.Yield 86%, m.p200 oC.
(C14H11ClN2 ; Required : C, 69.28; H, 4.53; N, 11.54%; found : C, 69.26; H,
4.52; N, 11.50%).
[B] Synthesis of 6 – methyl – 2 - ( 4' - chlorolphenyl)imidazo [ 1,2-a ] pyridine
– 3 - carboxaldehyde :
Arranged 2.0 lit 4/N RBF equipped with stirrer, tharmopocket and condensor
in water bath. Charge 84ml DMF and 1.0 lit CHCl3 in RBF and cool at 0 - 5 oC. Start
drop wise addition of 165ml POCl3 within 1.0 hrs. (exothermicity observe) stir 30
min at 0-5 oC. Add 50g (0.225 mole) 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-
a]pyridine slowly temp. raise up to reflux for 6 hrs. Remove CHCl3 by vacuum
distillation. Cool the reaction mass at room temperature and pour in crused ice. PH
adjust neutral by coustic solution. Filter and crystallized from methanol. Yield 70%,
mp180 oC.
(C15H11ClN2O ; Required : C, 71.33; H, 5.99; N, 11.55%; found : C, 71.33; H, 5.99;
N, 11.55%).
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine (1i)
Dissolve - 6 - methyl – 2 - ( 4' – chlorophenyl ) imidazo [ 1,2 – a ] pyridine
3-carboxaldehyde (2.91gm,0.01mol) in a mixture of methanol (50 ml) + DMF (50
ml). To this add p-methylacetophenone (1.40gm, 0.01mol) and methanol (50 ml).
Stirr the content at room temperature for 24 hr. in presence of catalytical amount of
40% NaOH. The resulting solution was poured on to crushed ice, thus the solid
0seprated was filterated and crystallized from ethanol, Yield 56 %, m. p. 184oC
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(C24H19ClN2O ; Required : C, 74.51; H, 4.95; N, 7.24%; found : C, 74.50; H, 4.93; N,
7.22%;
Similarly, other2-(4'-chlorophenyl)-6-methyl- 3-[1"-aryl- 2"-propene-1"-one-
3-yl ]-imidazo [1,2-a]pyridine compounds were prepared. The physical data are
recorded in Table no.1
[D] Biological Screening of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-aryl- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
All the compounds have been evaluated for their biological screening represented in
graphical chart no.-1
(I) Antibacterial activity650
The purified products were screened for their antibacterial activity using cup-
plate agar diffusion method. The nutrient agar broth prepared by the usual method
was inoculated aseptically with 0.5 ml of 24 hr. old subcultures of Bacillus
megaterium, Salmonella taphimurium, staphylo coccus aureus, Escherichia coli in
separate conical flasks at 40-50 oC and mixxed well by gentle shaking. About 25 ml
content of the flask was poured and evenly spreaded in a petridish (13 cm diameter)
and allowed to set for 2 hrs. The cups (10 mm diameter) were formed by the help of
borer in agar medium and filled with 0.05ml (50μg) solution of sample in DMF.
The plates were incubated at 37 oC for 24 hrs. and the control was also
maintained with 0.05ml of DMF in a similar manner and the zone of inhibition of the
bacterial growth were measured in millimeter and recorded in Table No-A.
(II) Antifungal activity650
Aspergillus niger was employed for testing antifungal activity using cup-plate
agar diffusion method. The culture was maintained on sabourauds agar slants
sterilized sabourauds agar medium was inoculated with 72 hrs. old 0.5ml suspension
of fungal spores in a separate flask.
About 25 ml of the inoculated medium was evenly spreaded in a petridish
(13cm diameter) and allowed to set for 2 hrs, the cups (10mm diameter) were
punched. The plates were incubated at 30 oC for 48 hrs.
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After the completion of incubation period, the zone of inhibition of growth in
the form of diameter in mm was measure. Along the test solution in each petridish one
cup was filled up with solvent, which acts as control. The zones of inhibition of test
solution are recorded in TableNo. A




Gram positive bacteria : Bacillus megaterium,
Salmonella taphimurium,
Gram negative bacteria : staphylo coccus aureus,
Escherichia coli
Fungi : Aspergillus niger
Concentration : 50µg/ml
Solvent : Dimethyl formamide
Standard drugs : Ampicillin,Chloramphenicol,
Norfloxacin
Greseofulvin.
The biological screening was compared with standard drug viz Ampicillin,
Chloramphenicol, Norfloxacin, and antifungal activity was compared with viz
Greseofulvin. The inhibition zones were measured in mm,The zones of inhibition that
displayed by standared drugs are recorded in part-I, page no.41, Table no-A.
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TABLE NO.A : ANTIMICROBIAL ACTIVITY ZONE OF INHIBITION OF STANDARD DRUGS.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
Drugs B. mega S. aureus E-coli S. typhi A. niger
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
Greseofulvin (50 µg) -- -- -- -- 22
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TABLE NO.1 PHYSICAL CONSTANTS OF 2 - ( 4' – CHLOROPHENYL )-6-METHYL- 3-[1"-(ARYL)- 2"-ROPENE-1"-ONE-3-YL
]-IMIDAZO [1,2-a] PYRIDINES.





1a C6H5- C23H17ClN2O 372.5 101 61 7.51 7.49
1b 3-Cl-C6H4 - C23H16Cl2N2O 407.0 245 63 6.88 6.86
1c 4-Cl-C6H4 - C23H16Cl2N2O 407.0 250 59 6.88 6.86
1d 2-4-(Cl)2-C6H3- C23H15Cl3N2O 441.5 205 55 6.34 6.32
1e 4 -F-C6H4- C23H16ClFN2O 390.5 126 69 7.17 7.15
1f 4-Br-C6H4- C23H16BrClN2O 451.5 170 60 6.20 6.17
1g 4 -OH-C6H4- C23H17ClN2O2 388.5 140 51 7.20 7.18
1h 4-NH2-C6H4 C23H18ClN3O 387.5 190 58 10.83 10.82
1i 4-CH3-C6H4- C24H19ClN2O 386.5 184 56 7.24 7.22
1j 4-OCH3-C6H4- C24H19ClN2 O2 402.5 180 70 6.95 6.93
1k 3-NO2-C6H4- C23H16ClN3O3 417.5 111 69 10.06 10.04
1l 4-NO2-C6H4- C23H16ClN3O3 417.5 250 50 10.06 10.04
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GRAPHICAL CHART NO.1: BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-[1"-(ARYL)- 2"-






















B.mega 16 15 14 21 18 12 15 20 15 22 16 14 22 22 22 0 0
S.aureus 15 18 16 19 15 15 19 15 20 21 20 15 19 23 22 0 0
E.coli 18 19 20 22 17 16 23 18 15 18 23 17 19 22 24 0 0
S. typhi 17 14 16 22 23 18 16 16 19 21 16 19 22 25 23 0 0
A.niger 14 15 18 22 16 14 15 17 20 22 20 14 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-I
SECTION – I: BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-[1"-ARYL - 2"- PROPENE-1"-ONE-3-
YL ]-IMIDAZO [1,2-a]PYRIDINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E. coli S. typhi A. Niger
1d-(21) 1d-(19) 1c-(20) 1d-(22) 1d-(22)
1h-(20) 1g-(19) 1d-(22) 1e-(23) 1i- (20)
1j-(22) 1i- (20) 1g-(23) 1j-(21) 1k-(20)
1j-(21) 1k-(23) 1j-(22)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --










Amongst nitrogen containing five member heterocycles, pyrazolines have
proved to be the most useful frame work for biological activities.The chemistry of
pyrazoline was reviewed by Jarobe in 1967. The chemistry of pyrazolines, which have
been studied extensively for their biodynamic behavior132. Pyrazoline has three










Different methods for the preparation of 2-pyrazoline derivatives are as
follows.









2. 2-Pyrazolines can be synthesized by the cycloaddition of diazomethane to
substituted chalcone134.
3. Dipolar cycloaddition of nitrileimines of dimethyl fumarate, fumaronitrile and
the N-aryl maleimides yielded the corresponding pyrazolines135.
4. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine
hydrate and phenyl hydrazine to give pyrazolines136.
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5. 2 - Pyrazolines can also be prepared by the condensation of chalcone
dibromide with hydrazine137. Furthermore, Gyassi B.et al138have investigated
the one pot synthesis of some pyrazolines in dry media under microwave
irradiation. Paul S.et al.139and Dandia Anshu et al.140 have also described the
microwave synthesis of 2-pyrazolines.
MECHANISM :
The following mechanism seems to be operable for pyrazoline by the




































Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated
carbonyl system forms species (II), in which the -ve charge is mainly accommodated
by the electronegative oxygen atom.
Proton transfer from the nitrogen to -ve oxygen produces an intermediate enol
which simultaneously ketonises to ketoamine (III). Another intramolecular
nucleophilic attack by the primary amino group of ketoamine on its carbonyl carbon
followed by proton transfer from nitrogen to oxygen leads ultimately to carbonyl
amine (IV). Later with a hydroxy group and amino group on the same carbon lose
water molecule to yield the pyrazolines. The study of pyrazoline nucleus are as under.
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THERAPEUTIC IMPORTANCE :

















E. Palska et al.161 have prepared 3,5-diphenyl-2-pyrazolines (II) and cited their
antidepressant activity. N. Gokhan et al.162 reported pyrazolines as cholinstearase and
selective monoamine oxidase B inhibitiors .T. M. Stivenson et al.163have also
investigated N-substituted pyrazoline type insecticides. Tanka Katsoshori164 have
patented pyrazoline derivatives as herbicides and Johannes et al.165 have reported as
insecticides.













R2= H,Cl, ( II )
M. M. Abdalla et al.166 have synthesized pyrazolines and tested their
antiandrogenic activity. M. A.Berghot et al.167 have prepared pyrazolines as
antibacterial agents. Maurer Fritz et al.168 have synthesized pyrazoles and screened for
their pesticidal activity.
A. R. Udupi and A. R.Bhatt 169 have reported the synthesis and biological
activity of Mannich bases of certain 1,2-pyrazolines. Nugent Richard170 investigated
pyrazolines bis phosphonate ester as novel antiinflammatory and antiarthritic agent.
Fuche Rainer etal.171 have prepared some new 1H-pyrazoline derivatives (III) and
reported them as pesticides. Furthermore, Tsubai et al.172 have synthesized some new
(phenylcarbamoyl) pyrazolines (IV) as an insecticides and at 40% concentration











(III) ( IV )
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Moreover, J. H.Ahn et al.173 have described the synthesis and DP-IV inhibition
of cyano-pyrazoline derivatives as potent antidiabetic agents(V). J. H. Jeong. et al.174
have synthesized some novel 3,5-diaryl pyrazolines as cholesterol acyl transferase
inhibitors. M. N Nasr. et al.175 have reported the synthesis of Novel 3,3a,4,5,6,7-
hexahydroindazole and aryl thiazolylpyrazoline derivatives as antiinflammatory
agents. M. A Berghot. et al.176 have prepared for convergentsynthesis and

















J. Almstead et al.177 have prepared pyrazolines as vascularization agent. Guniz
Kucukguzel et al.178 have synthesized pyrazolines as a anticonvulsant agents. T.
Gulhan and coworkers179 have prepared pyrazolines as a hypotensive agent. Shalabh
Sharma et al.180 have synthesized pyrazolines and tested their anti-inflammatory
activity (VI). Ashok Kumar et al.181 have synthesized pyrazolines as anticonvulsant






















( I ) ( II )
Recently, N. Gokhan et al.183 have synthesized the pyrazoline derivatives of 1-N-
substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines as MAO inhibitors. J.
Matysiak et al.184 have reported some novel pyrazoline derivatives as antimycotic
activity of N-azolyl-2,4-dihydroxythiobenzamides. Z. Tabarelli et al.185 have prepared
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some pyrazole derivative showed activity of antinociceptive effect of novel
pyrazolines in mice.
S. S. Sonarc et al.186 have synthesized-3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines and tested their antimicrobial activity. H. S. Joshi187
et al. have also synthesized some new pyrazolines as an antimicrobial agent. G. N.
Mishirikaet al.188 have prepared 2-pyrazolines of salicyclic acid possessing
antimicrobial properties. Tunfawy Atif and co-workers189 have patented 3-methyl-4'-
(substituted phenylazo)-pyrazol-5-ones as antibacterial agents.
With a view to get better therapeutic agent, it was contemplated to synthesize
pyrazoline derivatives to enhance the overall activity of resulting compounds which
have been described as under.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-
CHLOROPHENYL)-6-METHYL-3-(3"-ARYL -4", 5"-
DIHYDRO-1"H-PYRAZOL-5"-YL) IMIDAZO [1, 2-a]
PYRIDINES.
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-
CHLOROPHENYL)-6-METHYL-3-(3"-ARYL -1"-ACETYL-4",
5"- DIHYDROPYRAZOL-5"-YL) IMIDAZO [1, 2a]
PYRIDINES.
SECTION-III: SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-
CHLOROPHENYL)-6- METHYL-3-(3"-ARYL-1"-PHENYL-4",
5"-DIHYDROPYRAZOL-5"-YL) IMIDAZO [1, 2-a]
PYRIDINES.
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SECTION – I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)
– 6 – METHYL – 3 - (3" - ARYL - 4", 5" – DIHYDRO -1"H-PYRAZOL-5"-YL)
IMIDAZO [1, 2-a] PYRIDINES.
The broad spectrums of pharmacological properties have been demonstrated by the
pyrazoline nucleus. Inspired by these facts, new pyrazoline derivatives of 2-(4'-
chlorophenyl)-6-methyl-3-(3"-aryl -4", 5"-dihydro-1"H-pyrazol-5"-yl) imidazo [1, 2-
a] pyridines of Type (II) have been synthesized by condensation of 2-(4'-
chlorophenyl)-6-methyl- 3-[1"-aryl- 2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs.The details have been cited in part-I,section-I , page no. 41,Table no. A
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IR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL-3-[3"-
(4'''-METHYLPHENYL)-4",5"-DIHYDRO-1"H-PYRAZOL-5"-YL] IMIDAZO
[1, 2-a] PYRIDINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2949 2990-2850 648
C-H str. (sym.) 2879 2880-2860 "
C-H def. (asym.) 1452 1470-1435 "
Alkane
C-H def. (sym.) 1390 1390-1370 "
C-H str. 3090 3090-3030 "
C=C str 1502 1600-1450 "
Aromatic
C-H i.p. (def.) 1122 1300-1100 "
C-N str 1095 1230-1020 649
C=N str 1560 1650-1550 "
N-H str 3306 3320-3140 "
Pyrazoline
-CH-(CH)2 str. 2754 2850-1790 "
C-N str. 1058 1220-1020 "Imidazo[1,2-a]
pyridine C=N str. 1600 1612-1593 "
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NMR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL-3-[3"-
(4'''-METHYLPHENYL]4",5"-DIHYDRO-1"H-PYRAZOL-5"-YL) IMIDAZO
[1, 2-a] PYRIDINE.








1 2.21 3H Singlet Ar-CH3(k)
2 2.31 3H Singlet Ar-CH3(l)
3 3.16-3.31 1H ddoublet Ar- H(i)
4 3.43-3.52 1H ddoublet Ar-H(j)
5 5.41-3.51 1H quatret Ar-H(h)
6 7.14-7.17 1H doublet Ar-H(f)
7 7.19-7.22 2H doublet Ar-H(cc')
8 7.47-7.57 5H multiplate Ar-H(aa',bb',e)
9 7.72-7.75 2H doublet Ar-H(dd')
10 8.09 1H Singlet Ar-H(g)
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MASS SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL-3-[3"-(4'''-METHYLPHENYL)-4",5"-DIHYDRO-1"-H-























































































































TEA Reflux 4 hrs.
CHCl3
Reflux 6 hrs
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL-3-(3"-ARYL) -4", 5"-DIHYDRO-1"-H-PYRAZOL-5"-YL)
IMIDAZO [1, 2-a] PYRIDINES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I,on page no.37
[B] Synthesis of 6-methyl-2-(-4'chlorolphenyl)imidazo[1,2-a]pyridine-3-
Carboxaldehyde.
See, Part-I, Section-I , on page no.37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I,on page no.37
[D] Synthesis of 2-(4'-chlorophenyl)-6-methyl-3-[3"-(4"'-methylphenyl) -4",
5"-dihydro-1"-H-pyrazol-5"-yl] imidazo [1, 2-a] pyridines(2i).
A mixture of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a] pyridine (3.82 g, 0.01 mol) and hydrazine
hydrate 1.0g (0.02mol) in 25 ml methanol. The reaction mixture was reflux for 5 hrs.
the content was poured in to crused an ice,filtered dried and recrystllized from
ethanol. Yield 72 %, m.p. 170oC.
(C24H21ClN4 Requires : C,71.90, H,5.28, N,13.98%, Found : C,71.88, H,5.26,
N,13.95%).
Similarly, other 2-(4'-chlorophenyl)-6-methyl-3-(3"-aryl) -4", 5"-dihydro-
1"-H-pyrazol-5"-yl) imidazo [1, 2-a] pyridines were prepared. The physical data are
recorded in Table no.2.
[E] Biological screening of 2-(4'-chlorophenyl)-6-methyl-3-(3"-aryl) -4", 5"-
dihydro-1"-H-pyrazol-5"-yl) imidazo [1, 2-a] pyridines.
Biological screening were carried out as described in Part-I, Section-I. page
no. 38,The zones of inhibition of test solutions are recorded in Graphical Chart no.2.
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TABLE NO. 2 PHYSICAL COSTANTS OF 2- (4'-CHLOROPHENYL)-6-METHYL-3-(3"-ARYL -4", 5"-DIHYDRO-1"-H-
PYRAZOL-5"-YL) IMIDAZO [1, 2-a] PYRIDINES.





2a C6H5- C23H19ClN4 386.5 160 65 14.48 14.45
2b 3-Cl-C6H4 - C23H18Cl2N4 421.0 155 72 13.30 13.27
2c 4-Cl-C6H4 - C23H18Cl2N4 421.0 145 55 13.30 13.27
2d 2-4-(Cl)2-C6H3- C23H17Cl3N4 455.5 205 50 12.29 12.27
2e 4 -F-C6H4- C23H18ClFN4 404.5 185 65 13.84 13.81
2f 4-Br-C6H4- C23H18BrClN4 465.5 198 60 12.04 12.01
2g 4 -OH-C6H4- C23H19ClN4O 402.5 182 59 13.91 13.88
2h 4-NH2-C6H4 C23H20ClN5 401.5 210 62 17.43 17.40
2i 4-CH3-C6H4- C24H21ClN4 400.5 170 72 13.98 13.95
2j 4-OCH3-C6H4- C24H21ClN4O 416.5 165 50 13.44 13.41
2k 3-NO2-C6H4- C23H18ClN5O2 431.5 150 58 16.22 16.20
2l 4-NO2-C6H4- C23H18ClN5O2 431.5 190 66 16.22 16.20
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GRAPHICAL CHART NO. 2 : BIOLOGICAL SCREENING OF 2 - ( 4' – CHLOROPHENYL ) – 6 – METHYL -3 - ( 3"- ARYL - 4",






















B.mega 12 20 15 20 21 13 13 22 15 17 18 14 22 22 22 0 0
S.aureus 22 14 17 14 15 21 17 14 20 19 23 17 19 23 22 0 0
E.coli 20 17 14 19 15 16 24 16 14 17 21 17 19 22 24 0 0
S. typhi 17 13 15 23 16 19 15 19 16 22 23 13 22 25 23 0 0
A.niger 18 14 19 22 19 20 16 16 19 17 15 21 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-II
SECTION – I: BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-6-METHYL-3-(3"-ARYL -4", 5"DIHYDRO-1"-H-
PYRAZOL-5"-YL) IMIDAZO [1, 2-a] PYRIDINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E. coli S. typhi A. Niger
2b-(20) 2a-(22) 2a-(20) 2d-(23) 2d-(22)
2d-(20) 2f-(21) 2d-(19) 2j- (22) 2f- (20)
2e-(21) 2i- (20) 2g-(24) 2k-(23) 2l-(21)
2h-(22) 2j-(19) 2k-(21)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
Greseofulvin (50 µg) -- -- -- -- 22
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SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL-3-(3"-ARYL) -1"ACETYL-4", 5"-DIHYDROPYRAZOL-5"-YL)
IMIDAZO [1, 2-a] PYRIDINES.
Acetyl pyrazoline derivetives procuring better therapeutic and antimicrobial
activities. Looking at their versatile therapeutic importance and with an aim to getting
better potential drug, it was considered worthwhile to synthesized some new
pyrazolines. The preparation of 2-(4'-chlorophenyl)-6-methyl-3-(3"-aryl) -1"-acetyl-
4", 5"-dihydropyrazol-5"-yl) imidazo [1, 2-a] pyridines of Type (III) have been


















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I , page no. 41
.
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IR SPECTRAL STUDY OF 2 - (4'-CHLOROPHENYL)-6-METHYL-3-[3"-
(4"'-METHYLPHENYL) - 1" –ACETYL -4", 5" – DIHYDROPYRAZOL - 5"
– YL ] IMIDAZO [1, 2-a] PYRIDINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2958 2990-2850 648
C-H str. (sym.) 2877 2880-2860 "
C-H def. (asym. 1467 1470-1435
Alkane
C-H def. (sym.) 1388 1390-1370 "
C-H str. 3047 3090-3030 "
C=C str 1467 1600-1450 "
Aromatic
C-H i.p. (def.) 1141 1300-1100 "
C=O str 1690 1705-1650 "
C=N str 1602 1650-1550 649
Pyrazoline
-CH-(CH)2 str. 2793 2850-1790 "
C-N str. 1093 1220-1020 "Imidazo[1,2-a]
pyridine C=N str. 1600 1612-1593 "
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NMR SPECTRAL STUDY OF 2 - (4'-CHLOROPHENYL)-6-METHYL-3-[3"-
(4"'-METHYLPHENYL) - 1" –ACETYL -4", 5" – DIHYDROPYRAZOL - 5"
– YL ] IMIDAZO [1, 2-a] PYRIDINE.








1 2.28 3H singlet Ar-CO-CH3(k)
2 2.32-2.33 3H singlet Ar-CH3(l)
3 2.52 3H singlet Ar-CH3(m)
4 3.00-3.08 1H doublet Ar-H(i)
5 3.51-3.60 1H doublet Ar-H(j)
6 5.70-5.76 1H quatret Ar-H(h)
7 7.02-7.05 1H doublet Ar-H(f)
8 7.37-7.41 2H doublet Ar-H(aa')
9 7.51-7.41 2H doublet Ar-H(cc')
10 7.85-7.89 3H doublet Ar-H(bb',e)
11 8.10-8.14 2H doublet Ar-H(dd')
12 8.26 1H singlet Ar-H(g)
Vipul Bhuva Ph.D. Thesis Study on Acetyl Pyrazolines
65
MASS SPECTRAL STUDY OF 2 - (4'-CHLOROPHENYL)-6-METHYL-3-[3"-(4"'-METHYLPHENYL) - 1" –ACETYL -4", 5" –
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TEA Reflux 4 hrs.
CHCl3
Reflux 6 hrs
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL-3-(3"-ARYL) -1"-ACETYL-4", 5"-DIHYDROPYRAZOL-5"-YL)
IMIDAZO [1, 2-a] PYRIDINES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine.
See, Part-I, Section-I ,on page no.37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde.
See, Part-I, Section-I , on page no.37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-aryl- 2"-propene-
1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I,on page no.37
[D] Synthesis of 2-(4'-chlorophenyl)-6-methyl-3-[3"-(4"'-methylphenyl) –
1"-acetyl-4", 5"-dihydropyrazol-5"-yl] imidazo [1, 2-a] pyridines(3i).
A mixture of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyle) - 2"-
propene 1"-one-3-yl ]-imidazo [1,2-a]pyridine. (3.88 gm, 0.01 mol) and hydrazine
hydrate (0.5 gm, 0.01 mol), glacial acetic acid (2 ml) and methenol was refluxed
for 10 hrs. The reaction mixture poured in to crused an ice, filterd and dried it and
crystallized from ethanol. Yield 65%, m.p. 203oC.
(C26H23ClN4O ; Required : C, 70.50; H, 5.23; N, 12.65%; found : C, 70.48; H,
5.20; N, 12.63%;)
Similarly,Other 2-(4'-chlorophenyl)-6-methyl-3-(3"-aryl – 1"-acetyl-4", 5"-
dihydropyrazol-5"-yl) imidazo [1, 2-a] pyridines were prepared. The physical data
are recorded in Table No.3
[E] Biological Screening of 2-(4'-chlorophenyl)-6-methyl-3-(3"-aryl)-1"- acetyl-
4", 5"-dihydropyrazol-5"-yl) imidazo [1, 2-a] pyridines.
Biological Screening testing were carried out as described in Part-I , Section-I.
page no.38 The zones of inhibition of test solutions are recorded in Graphical Chart
No.3
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TABLE CNO. 3 PHYSICAL CONSTANTS OF 2-(4'-CHLOROPHENYL) – 6 – METHYL – 3 - ( 3" - ARYL -1"-ACETYL -4",5"-
DIHYDROPYRAZOL-5"-YL)IMIDAZO [1, 2-a] PYRIDINES.





3a C6H5- C25H21ClN4O 428.5 150 58 13.06 13.04
3b 3-Cl-C6H4 - C25H20Cl2N4O 463.0 190 51 12.09 12.07
3c 4-Cl-C6H4 - C25H20Cl2N4O 463.0 155 68 12.09 12.07
3d 2-4-(Cl)2-C6H3- C25H19Cl3N4O 497.5 180 60 11.25 11.23
3e 4 -F-C6H4- C25H20ClFN4O 446.5 145 60 12.54 12.52
3f 4-Br-C6H4- C25H20BrClN4O 507.5 198 55 11.03 11.01
3g 4 -OH-C6H4- C25H21ClN4O2 441.5 158 64 12.59 12.56
3h 4-NH2-C6H4 C25H22ClN5O 443.5 165 59 15.78 15.76
3i 4-CH3-C6H4- C26H23ClN4O 442.5 203 65 12.65 12.63
3j 4-OCH3-C6H4- C26H23ClN4O2 458.5 200 70 12.21 12.2
3k 3-NO2-C6H4- C25H20ClN5O3 473.5 167 54 14.78 14.76
3l 4-NO2-C6H4- C25H20ClN5O3 473.5 170 55 14.78 14.76
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GRAPHICAL CHART NO. 3 : BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL) – 6 – METHYL – 3 - ( 3" – ARYL -1"-






















B.mega 16 15 21 19 11 15 20 15 21 15 22 15 22 22 22 0 0
S.aureus 17 16 19 20 15 17 21 12 16 23 15 12 19 23 22 0 0
E.coli 19 17 20 16 17 15 22 16 17 23 15 17 19 22 24 0 0
S. typhi 15 17 22 23 17 18 17 23 15 17 23 17 22 25 23 0 0
A.niger 21 18 16 17 21 15 22 18 19 16 14 18 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-II
SECTION – II: BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL) – 6 – METHYL – 3 - ( 3" – ARYL -1"-ACETYL-
4",5"-DIHYDROPYRAZOL-5"-YL)IMIDAZO [1, 2-a] PYRIDINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E. coli S. typhi A. niger
3c-(21) 3c-(19) 3a-(19) 3c-(22) 3a-(21)
3g-(20) 3d-(20) 3c-(20) 3d- (23) 3e-( 21)
3i- (21) 3g-(21) 3g-(22) 3h-(23) 3g- (22)
3k-(22) 3j- (23) 3j-( 23) 3k-(23)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
Greseofulvin (50 µg) -- -- -- -- 22
Vipul Bhuva Ph.D. Thesis Study on Phenyl Pyrazolines
72
SECTION-III
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL -3 - ( 3"- (ARYL)-1"-PHENYL-4",5"DIHYDROPYRAZOL-5"-YL
IMIDAZO [1, 2-a] PYRIDINES.
Various derivatives of phenyl pyrazolines exhibit interesting biological
properties like anticancer, antiinflammatory, anticonvulsant, antipyretic etc. With a
view to prepare more potential phenyl pyrazoline drug compounds, we have carried
out the synthesis of phenyl pyrazoline of 2-(4'-chlorophenyl)-6-methyl -3 - ( 3"- aryl-
1"-phenyl-4",5"dihydropyrazol-5"-yl )imidazo [1, 2-a] pyridines of Type-(IV), which
have been prepared by the condensation of chalcone of Type-(I) with phenyl















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I ,page no. 41
Vipul Bhuva Ph.D. Thesis Study on Phenyl Pyrazolines
73
IR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL-3-[3"-(4"'-
METHYLPHENYL) - 1" – PHENYL - 4" ,5" – DIHYDROPYRAZOL - 5"-
YL]IMIDAZO [ 1, 2-a ] PYRIDINE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
Mode Observd Reported
Ref.
C-H str.(asym.) 2974 2990-2850 648
C-H str. (sym.) 2881 2880-2860 "
C-H def. (asym.) 1442 1470-1435 "
Alkane
C-H def. (sym.) 1386 1390-1370 "
C-H str. 3037 3090-3030 "
C=C str 1506 1600-1450 "
Aromatic
C-H i.p. (def.) 1155 1300-1100 "
C-N str 1226 1230-1020 649
C=N str 1558 1650-1550 "
Pyrazoline
-CH-(CH)2 str. 2788 2850-1790 "
C-N str. 1093 1220-1020 "Imidazo[1,2-a]
pyridine C=N str. 1600 1612-1593 "
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NMR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL-3-[3"-
(4"'- METHYLPHENYL) - 1" – PHENYL - 4",5" – DIHYDROPYRAZOL -5"-
YL]IMIDAZO [1, 2-a] PYRIDINE.








1 2.33 3H Singlet Ar-CH3(k)
2 2.43 3H Singlet Ar-CH3(i)
3 4.24 3H Singlet Ar-OCH3(j)
4 7.17-7.20 1H Doublet Ar-H(f)
5 7.29-7.31 4H Doublet Ar-H(aa’,cc’)
6 7.44 1H Singlet Ar-H(h)
7 7.55-7.56 2H Doublet Ar-H(bb’')
8 7.63-7.65 1H Doublet Ar-H(e)
9 7.69 1H Singlet Ar-H(g')
10 7.91-7.93 2H Doublet Ar-H(dd’)
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MASS SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL-3-[3"-(4"'- METHYLPHENYL) - 1" – PHENYL - 4",5" –
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TEA Reflux 4-5 hrsReflux 4-5 hrs
CHCl3
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-
CHLOROPHENYL)-6-METHYL-3-(3"-(ARYL)-1"-PHENYL-4",5"-
DIHYDROPYRAZOL-5"-YL)IMIDAZO [1, 2-a] PYRIDINES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 6-methyl-2-(-4'chlorolphenyl)imidazo[1,2-a]pyridine-3-
carbaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I,on page no. 37
[D] Synthesis of 2-(4'-chlorophenyl)-6-methyl-3-[3"-(4"'-methylphenyl)-
1"-phenyl-4",5"-dihydropyrazol-5"-yl] imidazo [1, 2-a] pyridine(4i).
A mixture of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine (4.21g ,0.01 mol), and phenyl
hydrazine (1.18g ,0.01 mol) in 25 ml methanol reflux for 10 hrs. poured the reaction
mass in to the ice chilled water. The product was filter dryied and recrystllized from
ethanol. Yield 78 %, m.p.185 oC,
(C30H25ClN4. ; Required : C, 75.54; H, 5.28; N, 11.75%; found : : C, 75.52; H, 5.25;
N, 11.73%;)
Similarly Others 2 - ( 4' – chlorophenyl ) 6-methyl-3-(3"-(aryl)-1"-phenyl
4",5"-dihydropyrazol-5"-yl) imidazo [1, 2-a] pyridines. other were prepared. The
physical data are recorded in Table no.4.
[E] Biological screening of 2-(4'-chlorophenyl)-6-methyl-3-(3"-aryl-1"-
phenyl-4",5"-dihydropyrazol-5"-yl) imidazo [1, 2-a] pyridines.
Biological screening were carried out as described in Part-I, Section-I,page no.38,
The zones of inhibition of test solutions are recorded in Graphical Chart no.4.
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TABLE NO. 4 PHYSICAL CONSTANTS OF 2-(4'-CHLOROPHENYL) – 6 – METHYL – 3 - ( 3" – ARYL -1"-PHENYL-4",5"-
DIHYDRO PYRAZOL-5"-YL)IMIDAZO [1, 2-a] PYRIDINES.





4a C6H5- C29H23ClN4 462.5 165 60 12.10 12.08
4b 3-Cl-C6H4 - C29H22Cl2N4 497.0 168 65 11.26 11.24
4c 4-Cl-C6H4 - C29H22Cl2N4 497.0 175 68 11.26 11.24
4d 2-4-(Cl)2-C6H3- C29H21Cl3N4 531.5 160 55 10.53 10.51
4e 4 -F-C6H4- C29H22ClFN4 480.5 175 63 11.65 11.64
4f 4-Br-C6H4- C29H22BrClN4 541.5 160 72 10.34 10.32
4g 4 -OH-C6H4- C29H23ClN4O 478.5 163 60 11.70 11.68
4h 4-NH2-C6H4 C29H24ClN5 477.5 163 75 14.65 14.63
4i 4-CH3-C6H4- C30H25ClN4 476.5 185 78 11.75 11.73
4j 4-OCH3-C6H4- C30H25ClN4O 492.5 165 66 11.36 11.33
4k 3-NO2-C6H4- C29H22ClN5O2 507.5 185 65 13.79 13.78
4l 4-NO2-C6H4- C29H22ClN5O2 507.5 195 68 13.79 13.78
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GRAPHICAL CHART NO. 4 : BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL) – 6 – METHYL – 3 - ( 3" - ARYL –1"-






















B.mega 21 10 15 18 20 19 14 13 22 16 19 17 22 22 22 0 0
S.aureus 14 19 17 20 15 16 18 15 23 17 21 15 19 23 22 0 0
E.coli 18 12 16 19 17 16 23 14 17 14 24 17 19 22 24 0 0
S. typhi 13 22 16 18 23 17 21 16 19 24 16 17 22 25 23 0 0
A.niger 16 18 21 14 22 17 15 21 14 18 22 17 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-II
SECTION – III: BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL) – 6 – METHYL – 3 - ( 3" - ARYL –1"-PHENYL-4",5"-
DIHYDRO PYRAZOL-5"-YL)IMIDAZO [1, 2-a] PYRIDINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E. coli S. typhi A. niger
4a-(21) 4b-(19) 4a-(18) 4b-(22) 4c-(21)
4e-(20) 4d-(20) 4d-(19) 4e-(23) 4e-(22)
4i- (22) 4i- (23) 4g-(23) 4g- (21) 4h-(21)
4k-(21) 4k-(24) 4j- (24) 4k-(22)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --










Heterocyclic compounds such as pyran derivatives continue to be a rich source
of innovative chemistry because a number of pharmaceutical, dyestuff, sweety-
smelling substances, insecticide possess this ring system. Pyran ring system is also
present in large number of neturally ocuring coloured compounds, in vitamin-E,
hemorrhagic compounds in cloves, in certain alkaloids and other substances.
Pyran is a doubly unsaturated six membered ring system with a single oxygen
as hetero atom. The two double bonds may be conjugated as α,β or 1,2-pyran or
isolated as in α,δor 1,4-pyran.
A degree of stabilisation of the pyran nucleus is achieved by substituting
phenyl group in the 2 or 4 and preferably also in the 6 position.
SYNTHETIC ASPECT
Various methods for the preparation of pyran derivatives have been cited in
the literature.190-199
1. Reaction between α,β-unsaturated carbonyl system with (CH2CN)2 led to
corresponding 2-amino-3-cyano-4H-pyrans.200
2. Some alkylidene 2H-pyrans were synthesized201 by thermal electrolyting ring
closure of divinyl alkenyl.
3. J. Svete et al.202 have synthesized fused 3-amino-2H-pyran-2-ones by solid phase
synthesis and by solution phase paralled synthesis.
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5. H. Abdel Ghany et al.204 have prepared new pyran derivatives by condentation of 2-
coumarylidene malononitriles with active methylene containing compound.
MECHANISM
The reaction of malononitrile with α,β -unsaturated system leads to the
formation of cyano 4H-pyran via Michael addition as shown in figure.
THERAPEUTIC IMPORTANCE
Literature survey revealed that various pyrans have resulted in many potential drugs
and are known to possess a broad biological activity such as,
1. Anti HIV205, 206
2. Antifungal207-209






7. CNS active agent215
8. Cytotoxic216
9. Inhibitors of cell proliferation217
10. Gastric acid secretion inhibitor218
11. Antimicrobial219
12. Hypolipidemic220
Zwaagstra Mariel221 have newly synthesised pyran derivatives and tested for
antiashamatic activity. Boyer Frederick et. al.222 have prepared some new- 2-amino-3-
cyano-4H-pyran and reported anti HIV agent and antiviral activity. Y. U. A. Sharanin













Synthesis and anticancer activity of pyran (IV) containing flourine have been
reported by Mohamed S. El-gaby et. al.224 4H-pyran of type (V) were prepared to

































Vipul Bhuva, Ph.D. Thesis Study on Cyanopyrans
86
Some of the pyran derivatives (VI) have been patented for their use as
antihypertensive225, antiestogens226, antagonist227,228, antitumor229 and antiviral230
activities. Synthesis and biological activity of pyran ring system have been reported








El-Subbagh and co-workers232 have synthesized cyanopyran derivatives and
showed their antiviral activity. Corbou Romuld et al.233 have reported cyanopyran



















Moreover, Fathy F. Abdel-Latif et al.234 have reported the synthesis of 2-
amino-3-cyanopyran derivatives and studied their biological activity. P. M. Zhu et.
al.235 have prepared biologically active 2-amino pyran derivatives.
Y. Iwahashi and co-workers236 have synthesized 4-hydroxy-4H-
furo[3,2c]pyran-2(6H)-one, is one of the best characterized and most widely
disseminated mycotoxinsfound in agriculrueal products. Y. Osada et al.237 investigated
antioxidative activity of 2,3-dihydro-3,5-dihydroxy-6-methyl-4H-pyran-4-one.
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Recently, T. Hanafusa et al.238 have reported some new cyanopyran as
functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by
tumor specific methylation. H. S. Williamson et al.239 have described pyran as a
truncated protein from enteropathogenic Escherichia coli acts as an antagonist. H.
Yeo and Y.Li et al.240 have described the synthesis and antiviral activity of
helioxanthin analogues. M. H DavidCordonnier. et al.241 have synthesized pyrano
compounds as antitumor agents.
Morever, C. Asche et al.242 have reported some novel cyanopyran for
antitumour activity and structure-activity relationships of 5H-benzo[b]carbazoles. C.
H Moon et al.243 have found some novel benzopyran analog, attenuates hypoxia-
induced cell death via mitochondrial KATP channel and protein kinase C-epsilon in
heart-derived H9c2 cells. A.Y Howe. et al.244 have described some novel
nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. K. Y.
Kim et al.245 investigated anti-apoptotic action of (2S,3S,4R)-N”-cyano-N-(6-amino-
3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N’-
benzylguanidine.
With this in view and in continuation of our research worck on new
heterocyclics of pharmacological interest, we report here in some new cynopyran
derivatives.
SECTION – I :SYNTHESIS AND BIOLOGICAL SCREENING OF 2"-AMINO
-4"-[2-(4'-CHLOROPHENYL) -6-METHYL IMIDAZO [1, 2-a]
PYRIDIN-3-YL]-6"-ARYL-4"-H-PYRAN-3"- CARBONITRILES
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SECTION – I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2"-AMINO-4"-[2-(4'-
CHLOROPHENYL) -6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-
ARYL- 4"-H-PYRAN-3"- CARBONITRILES.
3-Cyano-4,6-disubstituted 4H-pyrans are endowed with a variety of
pharmacodynamic activities such as anticonvulsant, antiinflammatory,
antihypertensive, antitumor etc. Looking to the interesting properties of cyanopyrans,
it was considered worthwhile to synthesis some new 2"-amino-4"-[2-(4'-
chlorophenyl) -6-methyl imidazo [1, 2-a] pyridin-3-yl]-6"-aryl- 4"-H-pyran-3"-
carbonitriles of Type ( V ) have been synthesized by condensation of chalcone of


















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I,page no. 41
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IR SPECTRAL STUDY OF 2"-AMINO-4"-[2-(4'-CHLOROPHENYL) -6-
METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-(4'''-METHYLPHENYL)- 4"-
H-PYRAN-3"- CARBONITRILE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2990 2990-2850 648
C-H str. (sym.) 2880 2880-2860 "
C-H def. (asym. 1444 1470-1430 "
Alkane
C-H def. (sym.) 1359 1395-1370 "
C-H str. 3051 3090-3030 "
C=C str 1487 1600-1450 "
Aromatic
C-H i.p. (def.) 1120 1300-1100 "
C=N str. 1598 1612-1593 649Imidazo[1,2-a]
pyridine C-N str. 1027 1220-1020 "
Pyrane N=H str. (-NH2) 3284 3350-3250 "
Nitril C=N str. 2190 2240-2120 "
C-N str. 1633 1650-1520 "
Ether C-O-C 1228 1260-1200 "
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NMR SPECTRAL STUDY OF 2"-AMINO-4"-[2-(4'-CHLOROPHENYL) -6-
METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-(4'''-METHYLPHENYL)- 4"-
H-PYRAN-3"- CARBONITRILE.








1 2.33 3H singlet Ar-CH3(k)
2 2.43 3H singlet Ar-CH3(i)
3 4.24 3H singlet Ar-OCH3(j)
4 7.17-7.20 1H doublet Ar-H(f)
5 7.29-7.31 4H doublet Ar-H(aa’,cc’)
6 7.44 1H singlet Ar-H(h)
7 7.55-7.56 2H doublet Ar-H(bb’')
8 7.63-7.65 1H doublet Ar-H(e)
9 7.69 1H singlet Ar-H(g')
10 7.91-7.93 2H doublet Ar-H(dd’)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2"-AMINO-4"-[2-(4'-
CHLOROPHENYL) -6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-
ARYL- 4"-H-PYRAN-3"- CARBONITRILES
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyle)-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no.37
[D] Synthesis of 2"-amino-4"-[2-(4'-chlorophenyl)-6-methylimidazo[1, 2-a]
pyridin-3-yl]-6"-(4"'-methylphenyl)-4"-H-pyran-3"-carbonitrile(5i).
A mixture of 2-(4'-chlorophenyl)-6-methyl-3-[1"-( 4"'-methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine (2.74 gm, 0.01 mol) and malononitrile
(0.66gm, 0.01 mol) in pyridine (20 ml), was heated under reflux for 12 hrs. on oilbath.
The reaction mixture was cooled and poured on to crushed ice. The product was
neutralized with 20% HCl, where upon a solid separated out, which was filtered dried
and crystallized from ethanol. Yield 65%, m.p.165oC
(C27H21ClN4O ; Required : C, 71.60; H, 4.67; N, 12.37%; found C, 71.58; H, 4.65; N,
12.35%; )
Similarly, other 2"-amino-4"-[2-(4'-chlorophenyl) -6-methyl imidazo [1, 2-a]
pyridin-3-yl]-6"-aryl - 4"-H-pyran-3"- carbonitriles were prepared. The physical data
are recorded in Table No.5
[E] Biological Screening of 2"-amino-4"-[2-(4'-chlorophenyl) -6-methyl
imidazo [1, 2-a] pyridin-3-yl]-6"- (aryl) - 4"-H-pyran-3"- carbonitriles.
Biological Screening were carried out as described in Part-I , Section-
1,page no.38 The zones of inhebition of test solution are recorded in
Graphical Chart No 5.
Vipul Bhuva, Ph.D. Thesis Study on Cyanopyrans
95
TABLE NO. 5 PHYSICAL CONSTANTS OF 2"-AMINO-4"-[2-(4'-CHLOROPHENYL) -6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-
YL]-6"-(ARYL)- 4"-H-PYRAN-3"- CARBONITRILES.





5a C6H5- C26H19ClN4O 438.5 180 48 12.77 12.72
5b 3-Cl-C6H4 - C26H18Cl2N4O 473.0 165 72 11.84 11.81
5c 4-Cl-C6H4 - C26H18Cl2N4O 473.0 155 68 11.84 11.80
5d 2-4-(Cl)2-C6H3- C26H17Cl3N4O 507.5 195 65 11.03 11.01
5e 4 -F-C6H4- C26H18ClFN4O 456.5 183 55 12.26 12.22
5f 4-Br-C6H4- C26H18BrClN4O 517.5 200 53 10.82 10.80
5g 4 -OH-C6H4- C26H19ClN4O2 454.5 175 60 12.32 12.30
5h 4-NH2-C6H4- C26H20ClN5O 453.5 210 50 15.43 15.41
5i 4-CH3-C6H4- C27H21ClN4O 452.5 165 65 12.37 12.35
5j 4-OCH3-C6H4- C27H21ClN4O2 468.5 190 63 11.95 11.90
5k 3-NO2-C6H4- C26H18ClN5O3 483.5 166 58 14.97 14.91
5l 4-NO2-C6H4- C26H18ClN5O3 483.5 177 55 14.97 14.95
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GRAPHICAL CHART NO. 5 : BIOLOGICAL SCREENING OF 2"-AMINO-4"-[2-(4'-CHLOROPHENYL) -6-METHYL IMIDAZO






















B.mega 13 18 22 19 18 21 13 21 19 18 17 15 22 22 22 0 0
S.aureus 14 15 23 14 15 20 16 15 15 20 19 17 19 23 22 0 0
E.coli 16 16 24 16 16 15 17 20 18 22 17 16 19 22 24 0 0
S. typhi 16 14 17 21 16 24 14 19 16 24 22 14 22 25 23 0 0
A.niger 17 15 15 22 21 19 18 19 18 18 15 21 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-III
SECTION – I: BIOLOGICAL SCREENING OF 2"-AMINO-4"-[2-(4'-CHLOROPHENYL) -6-METHYL IMIDAZO [1, 2-a]
PYRIDIN-3-YL]-6"-(ARYL)- 4"-H-PYRAN-3"- CARBONITRILES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
5c-(22) 5c-(23) 5c-(24) 5d-(21) 5d-(22)
5f-(21) 5f- (20) 5h-(20) 5f- (24) 5e-(21)
5h-(21) 5j-(20) 5i- (18) 5j- (24) 5l- (21)
5k-(19) 5j-(22) 5k-(22)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --










Pyridine, nucleus has been extensively explored for their applications in the
field of medicine, agriculture and industrial chemistry. Although many substituted
pyridine compounds like other heterocyclic compounds are synthesized with their
functional group present from a cyclic compounds. The simple pyridine compounds
are prepared by the cyclization of aliphatic raw material. The availability of 3-
cyanopyridines, nicotinamide and nicotinic acid make possible their use as synthetic
intermediates.
Most of pyridine derivatives are synthesized by manipulation of pyridine and
its simple homologues in a manner similar to chemistry of the benzenoid chemistry.
However the simple pyridine compounds are prepared by the cyclization of aliphatic
raw materials. In our continuation work in the chemistry of pyridine nucleus, we have
undrtaken the synthesis of imidazo[1,2-a]pyridine derivatives such as 2"–methoxy-4"-
[2-(4'-Chlorophenyl )–6 - methyl imidazo [ 1, 2 – a ] pyridine - 3 –yl]- 6"-aryl
nicotinonitriles via chlacones.
SYNTHETIC ASPECT :
Different methods for the preparation of 3-cyanopyridines are available in
literature.246-252
The well known methods are:
1. Substituted cyanopyridine derivatives were prepared from 3-substituted phenyl
pyrazolone derivatives with malononitrile.253
2.A.Samour and co-workers254 have prepared substituted cyanopyridines by the
condensation of chalcones with malononitrile in presence of ammonium acetate.
3. A.Sakurai and Midorikaw255, 256 have reported that malononitrile reacts with α, β-
unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines.
4. D. Bowman Matthew et al.257 have synthesized fluorescent cyanopyridine and
deazalumazine dyes using small molecule macroarrays.
5. Dao-Lin& wengetal258 have prepared 2-methoxy -3-cyano pyridine derivatives by
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The reaction proceeds through conjugate addition of active methylene
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THERAPEUTIC IMPORTANCE
Cyanopyridine have attracted considerable attention as they appeared of
interest to possess antibacterial, anticholestermic, antifungal, antihypertensive and










E.G.Hammana Abou and co-workers268 have studied anticancer and anti-HIV
activity of 3-cyanopyridines. N. A. Abdallah et al.269 have prepared cyanopyridine
derivatives which showed analgesic and antiinflammatory activity. M. Fedele and co-
workers270 have reported the antiinflammatory activity of 3-cyanopyridines. H.
Yoshida et al271 have studied the antihistamic and antiallergic activity of 3-
cyanopyridine derivatives.
A. El-Galil and co-workers272 have prepared 3-cyanopyridines (I) and studied
their pharmacological activity. G.S. Gadaginamath and co-workers273 have
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S. V. Roman et al.274 have synthesized 2-amino-3-cyanopyridines and reported
their biological activity. F.M.A.El-Taweel and co-workers275 have prepared
cyanopyridine derivatives and showed their significant biological activity.
M. Hussan and co-workers276 have prepared 3-cyanopyridines and reported
their pharmacological activity. U. D. Pyachenko et al.277 have synthesized some
cyanopyridines which are useful in the treatment of retroviral disease. K.Thiele et
al.278 have studied the analgesic activity of substituted 3-cyanopyridines.
N. Latif and co-workers279 have reported the antibacterial and antifungal
activity of 2-amino-3-cyano-4,6-disubstituted pyridines. M. Bernard et al.280 have
reported the anticonvulsant activity of 3-cyanopyridines. D. G. Bhatt et al.281 have
prepared 3-cyanopyridines as an immunosuppressisve agent. U. Teu and co-
workers282 have shown cyanopyridine as agrochemical fungicides.
J. A. Vann Allan et al.283 have prepared fused heterocyclic 3-cyanopyridine
(III). Abu and co-workers284 have prepared novel fused cyanopyridines (IV) for the

























A.Streightoff1285 and Seydal286 have studied the bacteriostatic effect of
somesubstituted 3-cyanopyridines.E. Francis and co-worker287 have studied the
effectof some substituted pyridines on the growth of the walker carcinosarcome in
tissue culture. E.D.Barton et. al.288 have reported fungicidal and insecticidalproperties.
W. Veb leuna and co-worker289 have studied 3- and 4-cyanopyridinesas tuberculosis
arresting agents.
El-Nabawia et al.290 have prepared 2-amino-3-cyano pyridine derivatives (V)
and studied their antimicrobial activity. S. Guru et al.291 have synthesized various
cyanopyridyl derivatives (VI) and documented their multiple biological activities.



















K. Kadlec and Hanslian292 showed that 2-methyl-3-nitro-4-methoxyethyl-5-
cyano-6-chloro pyridines caused occupational eczema in Vitamin B6 factory
workers. Rigterink and H.Raymond293 have studied the pesticidal activity of 3-
cyanopyridines. M. R. Pavia et al.294 have prepared N-substituted 2- aminopyridines
which possess anticonvulsant property. 3-Cyanopyridines reported by L. Castedo et
al.295 showed a minimum inhibitory concentration of 1.56 µg/ml against S. aureus.
W. Von Benbenburg and co-workers296 have synthesized 2-amino-3,6-
disubstituted pyridines as antiepileptic agents. V. Scott and E. Joseph297, 298 have
prepared 2-amino-3-cyanopyridine derivatives which were found to be useful as
antipsoriasis pharmaceuticals.
E.Abdel-Galil Amr and Mohamed M. Abdulla299 have synthesized
heterocyclic pyridine derivatives (VII) fused with steroidal structure. Initially the
acute toxicity of the compounds was assayed via the determination of their LD50.
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W. Von Benbenburg and co-workers300 have synthesized 2-amino-3,6-
disubstituted pyridines as antiepileptic agents. V. Scott and E. Joseph301, 302 have
prepared 2-amino-3-cyanopyridine derivatives which were found to be useful as
antipsoriasis pharmaceuticals.
Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a
valuable therapy for diabetes. Edwin B. Villhauer and co-workers303 have reported the
first use of solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and
a solution-phase synthesis that is practical up to the multikilogram scale.
J. L Marco. et al.304 have synthesized cyanopyridine and reported as
acetylcholinesterase inhibitors. M. A.Moustafa et al.305 have prepared cyanopyridine
as antibacterial agents. H. S. Eduardo Sousa et al.306 documented thionicotinamide
coordinated to the a model system for the in vitro activation of thioamides
antituberculosis drugs. Rosentreter Ulrich et al.307 have synthesized a new
cyanopyridine as receptor agonists in the treatment of cardiac or urogenital disease
cancer, inflammation, neurodegenerative disease(VIII). Gary T. Wang and co-
workers308 have synthesized o-trifluoromethylbiphenyl substituted 2-amino-






























A John. Tucker et al.309 have synthesized novel Piperazinyl Oxazolidinone
containing cyanopyridine (X) as an antibacterial agents.













In view of therapeutic activities shown by cyanopyridines, it was
contemplated to synthesize some new cyanopyridines in described as under.
SECTION-I : Synthesis and biological Screening of 2" – methoxy - 4" - [ 2
- (4'-Chlorophenyl)–6-methyl imidazo [1, 2 – a] pyridine -3–yl]- 6"-
aryl nicotinonitryles.
SECTION-II : Synthesis and biological Screening of 2" – amino - 4" - [ 2 -
(4'-chlorophenyl)–6-methyl imidazo [1, 2 – a ] pyridine – 3 –yl]-6"-
arylnicotinonitryles
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2" – METHOXY - 4" - [
2 - ( 4' -CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-
6"-ARYL NICOTINONITRILES.
Pyridine nucleus plays an important role in medicine, agriculture and
industrial chemistry. With a view of biological activities and variety of industrial
applications, some new 2" – methoxy - 4" - [ 2 - ( 4' -chlorophenyl)-6-methyl imidazo
[1, 2-a] pyridin-3-yl]-6"-aryl nicotinonitriles derivative of Type (VI) have been
prepared by the cyclocondensation of 2-(4'-chlorophenyl)-6-methyl- 3-(1"-aryl-
2"-propene-1"-one-3-yl) -imidazo [1,2-a] pyridines of Type (I) with malononitrile in



















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I ,page no. 41
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IR SPECTRAL STUDY OF 2" – METHOXY - 4" - [ 2 - ( 4' -
CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-(4'''-
METHYLPHENYL) NICOTINONITRILE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2923 2990-2850 648
C-H str. (sym.) 2894 2880-2860 "
C-H def. (asym. 1440 1470-1430 "
Alkane
C-H def. (sym.) 1373 1395-1370 "
C-H str. 3031 3090-3030 "
C=C str 1494 1600-1450 "
Aromatic
C-H i.p. (def.) 1151 1300-1100 "
C=N str. 1595 1612-1593 649Imidazo[1,2-a]
pyridine C-N str. 1117 1220-1020 "
C=N 1573 1580-1550 "
C=N str. 2200 2240-2120 "
Pyridine
Nitril
C-N str. 1560 1650-1520 "
Ether C-O-C 1209 1260-1200 "
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NMR SPECTRAL STUDY OF 2" – METHOXY - 4" - [ 2 - ( 4' -
CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-(4'''-
METHYLPHENYL) NICOTINONITRILE.








1 2.33 3H Singlet Ar-CH3(k)
2 2.43 3H Singlet Ar-CH3(i)
3 4.24 3H Singlet Ar-OCH3(j)
4 7.17-7.20 1H doublet Ar-H(f)
5 7.29-7.31 4H doublet Ar-H(aa’,cc’)
6 7.44 1H Singlet Ar-H(h)
7 7.55-7.56 2H doublet Ar-H(bb’')
8 7.63-7.65 1H doublet Ar-H(e)
9 7.69 1H Singlet Ar-H(g')
10 7.91-7.93 2H doublet Ar-H(dd’)
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EXPERIMENTALS
SYNTHESIS AND BIOLOGICAL SCREENING OF 2" – METHOXY - 4" - [
2 - ( 4' -CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-
6"-ARYL NICOTINONITRILES.
[A] Synthesis of 6– methy –2 - (4' -chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 6–methyl-2-( 4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesisof2-(4'-chlorophenyl)-6-methyl- 3-[1"-( 4"'-methylphenyle)-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no. 37
[D] Synthesis of 2" –methoxy -4" -[2 -( 4' -chlorophenyl)-6-methyl imidazo
[1, 2-a] pyridin-3-yl]-6"-( 4"'-methylphenyle) nicotinonitriles(6i)
To a solution of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-( 4"'-methylphenyle)-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine (3.88 gm, 0.01 mol), malononitrile
(0.60gm, 0.01 mol) and sodium methoxide in methanol (25ml). The content was
heated under reflux with stirring for 12 hrs. The reaction mixture was diluted with
water and extracted with chloroform. The excess solvent was distilled out and product
was crystallized from ethanol. Yield 62%, m.p. 159oC.
(C28H21ClN4O ; Required : C, 72.33; H, 4.55; N, 12.05 %; found : C, 71.31; H, 4.53;
N, 12.03 %;)
Similarly, other 2" – methoxy - 4" - [ 2 - ( 4' -chlorophenyl)-6-methylimidazo
[1, 2-a] pyridin-3-yl]-6"- aryl nicotinonitriles were prepared. The physical data are
recorded in Table No.-6
[E] Biological Screening of 2" – methoxy - 4" - [ 2 - ( 4' -chlorophenyl)-6-
methylimidazo [1, 2-a] pyridin-3-yl]-6"- aryl nicotinonitryles
Biological Screening were carried out as described in Part-I , Section-1,page
no. 38The zones of inhabition of test solution are recorded in Graphical Chart
No.-6
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TABLE NO. 6 PHYSICAL COSTANTS OF 2" – METHOXY - 4" - [ 2 - ( 4' -CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a]
PYRIDIN-3-YL]-6"-(ARYL) NICOTINONITRILES.





6a C6H5- C27H19ClN4O 450.5 190 65 12.43 12.40
6b 3-Cl-C6H4 - C27H18Cl2N4O 485.0 185 59 11.54 11.51
6c 4-Cl-C6H4 - C27H18Cl2N4O 485.0 170 52 11.54 11.52
6d 2-4-(Cl)2-C6H3- C27H17Cl3N4O 519.5 195 75 10.78 10.76
6e 4 -F-C6H4- C27H18ClFN4O 468.5 200 68 11.95 11.93
6f 4-Br-C6H4- C27H18BrClN4O 529.5 222 72 10.57 10.55
6g 4 -OH-C6H4- C27H19ClN4O2 466.5 180 48 12.00 12.00
6h 4-NH2-C6H4- C27H20ClN5O 465.5 165 59 15.03 15.01
6i 4-CH3-C6H4- C28H21ClN4O 464.5 159 62 12.05 12.02
6j 4-OCH3-C6H4- C28H21ClN4O2 480.5 160 60 11.65 11.61
6k 3-NO2-C6H4- C27H18ClN5O3 495.5 167 71 14.12 14.10
6l 4-NO2-C6H4- C27H18ClN5O3 495.5 188 66 14.12 14.11
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GRAPHICAL CHART NO. 6 : BIOLOGICAL SCREENING OF 2" – METHOXY - 4" - [ 2 - ( 4' -CHLOROPHENYL)-6-METHYL






















B.mega 16 18 19 14 15 18 21 20 21 17 16 14 22 22 22 0 0
S.aureus 15 19 13 14 22 14 17 15 23 14 17 15 19 23 22 0 0
E.coli 13 19 15 17 14 16 22 23 21 17 13 15 19 22 24 0 0
S. typhi 19 18 19 23 25 17 19 23 19 24 15 16 22 25 23 0 0
A.niger 14 19 18 21 18 19 18 22 17 17 14 13 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-IV
SECTION – I: BIOLOGICAL SCREENING OF 2" – METHOXY - 4" - [ 2 - ( 4' -CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a]
PYRIDIN-3-YL]-6"-(ARYL) NICOTINONITRILES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E. coli S. typhi A. niger
6g-(21) 6b-(19) 6b-(19) 6d-(23) 6d-(21)
6h-(20) 6e-(22) 6g-(22) 6e-(25) 6h-(22)
6i- (21) 6i-(23) 6h-(23) 6h-(23)
6i- (21) 6j-(24)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
Greseofulvin (50 µg) -- -- -- -- 22
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SECTION – II
SYNTHESIS AND BIOLOGICAL SCREENING OF 2" – AMINO - 4" - [ 2 -
( 4' -CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-
ARYL NICOTINONITRILES.
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of cyanopyridines. To further assess the potential of such class of
compounds, cyanopyridine derivatives of 2" – amino - 4" - [ 2 - ( 4' -chlorophenyl)-6-
methyl imidazo [1, 2-a] pyridin-3-yl]-6"-aryl nicotinonitryles of Type (VII) have been
prepared, by the cyclocondensation of 2-(4'-chlorophenyl)-6-methyl-3-(1"-aryl- 2"-
propene-1"-one-3-yl) -imidazo [1,2-a] pyridines of Type (I) with with malononitrile in



















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I ,page no. 41
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IR SPECTRAL STUDY OF 2" – AMINO - 4" - [ 2 - ( 4' -CHLOROPHENYL)-
6-METHYL IMIDAZO [1, 2- a] PYRIDIN-3-YL]-6"-(4'''-METHYLPHENYL)
NICOTINONITRILE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2941 2990-2850 648
C-H str. (sym.) 2894 2880-2860 "
C-H def. (asym. 1456 1470-1430 "
Alkane
C-H def. (sym.) 1384 1395-1370 "
C-H str. 3052 3090-3030 "
C=C str 1490 1600-1450 "
Aromatic
C-H i.p. (def.) 1168 1300-1100 "
C=N str. 1598 1612-1593 649Imidazo[1,2-a]
pyridine C-N str. 1083 1220-1020 "
N-H str. (-NH2) 3250 3350-3250 "
C=N str. 1558 1612-1550 "
Pyridine
Nitril
C-N str. 1186 1220-1020 "
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NMR SPECTRAL STUDY OF 2" – AMINO - 4" - [ 2 - ( 4' -
CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2- a] PYRIDIN-3-YL]-6"-(4'''-
METHYLPHENYL) NICOTINONITRILE.









1 2.22 3H singlet Ar-CH3 ( k )
2 2.26 3H singlet Ar-CH3 ( j )
3 4.92 2H singlet Ar-NH2 ( i )
4 6.91-6.98 1H doublet Ar-H ( f )
5 7.27-7.33 2H doublet Ar-H(dd')
6 7.39-7.43 2H singlet Ar-H ( aa' )
7 7.46-7.54 4H multiplet Ar-H ( bb',e,h)
8 7.69-7.72 2H doublet Ar-H ( cc' )
9 8.06 1H singlet Ar-H ( g )
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EXPERIMENTALS
SYNTHESIS AND BIOLOGICAL SCREENING OF 2" – AMINO - 4" - [ 2 -
( 4' -CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-6"-
ARYL NICOTINONITRILES
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl-3-[1"-(4"'- methylphenyle )-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no. 37
[D] Synthesis of 2"–amino - 4"-[2 -( 4'–chlorophenyl ) – 6 - methyl imidazo
[1, 2– a] pyridin –3–yl]- 6"-( 4"'-methylphenyl) nicotinonitriles(7i).
A mixture of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-( 4'" -methylphenyl)- 2"-
propene-1"-one-3-yl]-imidazo [1,2-a]pyridine. (3.40 g, 0.01 mol), malononitrile (0.66
g, 0.01 mol) and ammonium acetate (2.31 g, 0.03 mol) in DMF (30 ml) was refluxed
for 8 hrs., The content was poured in to crushed ice. The solid was obtained filtered,
washed with water and crystallised from dioxane. Yield 58%, m.p. 159 oC.
(C27H20ClN5 ; Required : C, 72.07; H, 4.48; N, 15.57 %; found : C, 72.07; H, 4.48; N,
15.56 %;)
Similarly other 2" – amino - 4" - [ 2 - ( 4' -chlorophenyl)-6-methyl imidazo [1,
2-a] pyridine 3-yl]-6"-aryl nicotinonitriles were synthesized. The physical data are
recorded in Table No.7
[E] Biological Screening of 2" – amino - 4" - [ 2 - ( 4' - chlorophenyl ) - 6-
methylimidazo [1, 2-a] pyridin-3-yl]-6"- (aryl) nicotinonitriles
Biological Screening were carried out as described in Part-I , Section-1 page
no.38 The zones of inhabition of test solution are recorded in Graphical Chart No. 7.
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TABLE NO. 7 PHYSICAL COSTANTS OF 2" – AMINO - 4" - [ 2 - ( 4' -CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2- a]
PYRIDIN-3-YL]-6"-(ARYL) NICOTINONITRILES.





7a C6H5- C26H18ClN5 435.5 210 72 16.07 16.05
7b 3-Cl-C6H4 - C26H17Cl2N5 470.0 180 62 14.89 14.87
7c 4-Cl-C6H4 - C26H17Cl2N5 470.0 195 55 14.89 14.86
7d 2-4-(Cl)2-C6H3- C26H16Cl3N5 504.5 160 68 13.87 13.85
7e 4 -F-C6H4- C26H17ClFN5 453.5 205 75 15.43 15.41
7f 4-Br-C6H4- C26H17BrClN5 514.5 165 55 13.60 13.59
7g 4 -OH-C6H4- C26H18ClN5O 451.5 190 62 15.50 15.48
7h 4-NH2-C6H4- C26H19ClN6 450.5 150 54 18.64 18.62
7i 4-CH3-C6H4- C27H20ClN5 449.5 159 58 15.57 15.56
7j 4-OCH3-C6H4- C27H20ClN5O 465.5 169 66 15.03 15.01
7k 3-NO2-C6H4- C26H17ClN6O2 480.5 177 71 17.48 17.45
7l 4-NO2-C6H4- C26H17ClN6O2 480.5 185 70 17.48 17.46
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GRAPHICAL CHART NO. 7 : BIOLOGICAL SCREENING OF 2" – AMINO - 4" - [ 2 - ( 4' -CHLOROPHENYL)-6-METHYL






















B.mega 16 18 19 22 21 19 18 16 15 22 16 13 22 22 22 0 0
S.aureus 14 16 21 19 17 16 17 22 17 15 21 16 19 23 22 0 0
E.coli 13 15 17 16 21 19 23 17 17 16 24 17 19 22 24 0 0
S. typhi 15 14 19 17 24 23 19 24 19 17 17 15 22 25 23 0 0
A.niger 17 14 19 22 21 18 18 22 16 19 12 13 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-III
SECTION – I: BIOLOGICAL SCREENING OF 2"-AMINO-4"-[2-(4'-CHLOROPHENYL) -6-METHYL IMIDAZO [1, 2-a]
PYRIDIN-3-YL]-6"-(ARYL)- 4"-H-PYRAN-3"- CARBONITRILES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
5c-(22) 5c-(23) 5c-(24) 5d-(21) 5d-(22)
5f-(21) 5f- (20) 5h-(20) 5f- (24) 5e-(21)
5h-(21) 5j-(20) 5i- (18) 5j- (24) 5l- (21)
5k-(19) 5j-(22) 5k-(22)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --










Pyrimidine derivatives like uracil (I), thymine (II) and cytosine (III) occur
widely in nature showing remarkable pharmaceutical importance because of their
diverse pharmacological activities. Pyrimidine derivatives which occurs in natural
products310 like nucleic acid, vitamin-B and having remarkable pharmaceutical
importance because of their broad spectrum of biological activities.Several analogues
of nucleic acid have been used as a compound that interfere with the synthesis and
function of nucleic acids, an example is fluorouracil which has been used in cancer
treatment. Pyrimidines are among those molecules that make like possible as being
some of the building blockers of DNA and RNA.
Pyrimidine is considered to be a resonance hybrid of the charged and
uncharged cannonical structures, its resonance energy has been found to be less than
benzene or pyridine. The naturally occuring pyrimidine derivatives was first isolated
by Gabrial and Colman in 1870, and its structure was confirmed in 1953 as 5-β-D-
gluco-pyranoside of Divicine.
SYNTHETIC ASPECT
A very important general method for preparing pyrimidines is the
condensation between a three carbon compounds of the type YCH2Z, where Y and Z
= COR, CO2R, CN, and compounds having the amidine structure R(C=NH)NH2,
where R=R (an amidine), SH or SR (thiourea or its s-derivative), NH2 (guanidine); the
condensation is carried out in the presence of sodium hydroxide or sodium ethoxide.
This general reaction may be illustrate by the condensation of acetamidine with
ethylacetoacetate to form 4-hydroxy-2,6-dimethylpyrimidine.
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The reaction of chalcone with guanidine hydrochloride in presence of
potassium t-butoxide in t-butanol yielded corresponding 2-amino pyrimidine
derivatives311. Pratibha Sharma and co-workers312 have investigated the insertion of
dimethylvinylidene carbine into azo moiety was investigated in order to synthesize
4,6-dimethyl-5-[2-(2-methylprop-1-enyl)-1H-benzimidazol-1-yl]pyrimidine-2(5H)-
thiones under kinetically controlled phase transfer catalysis conditions.
Rasaki313 synthesized 2-amino-pyrimidine by the reaction of chalcone
epoxides with guanidine carbonate in xylene. Sham M. Sondhi et al.314 have
synthesized pyrimidinederivatives by an efficient, one-pot reaction of functionalized
amines with either4-isothiocyanato-4-methyl-2-pentanone or 3-isothiocyanatobutanal.
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There are many other methods of pyrimidine ring synthesis which are of more
limited scope. The reaction of 1,3-dicarbonyl compound or an equivalent reagent with
formamide provides a route of several pyrimidine which are unsubstituted at the 2-
position.
REACTION MECHANISM
The reaction mechanism for the formation of pyrimidine derivatives described
as under.
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THERAPEUTIC IMPORTANCE
Large number of drugs possess pyrimidine ring system. Well-known
antimalarial agents like hypotensive agent like minoxidil (IV), pyrimethamine (V),





































Pyrimidine derivatives exhibit a wide spectrum of pharmacological activities











S. S. Sangopure325 have tested the antimicrobial activity of benzofuro[3,2
d]pyrimidine derivatives (VII). El Sayed326 have synthesized alkylated substituted
mercapto pyrimidine derivatives (VIII) and studied their anticancer and antineoplastic
activity. H. Y. Moustafa327 have reported some pyrimidine derivatives and studied
their biological activities.















( II) ( III)
Marie Gompel and co-workers328 have showed that meridianins inhibit various
protein kinases such as cyclin-dependent kinases, glycogen Synthase kinase-3, cyclic
nucleotide-dependent kinases and casein kinase (IX). H. Alistair et al.329 have
Synthesized a novel series of aminopyrimidine IKK-2 inhibitors which show excellent
in vitro inhibition of this enzyme and good selectivity over the IKK1 isoform. The
relativen potency and selectivity of these compounds has been rationalized using



















L. R Patil. et al.330 have synthesized some new pyrimidines bearing
paracetamol and imidazolyl moieties. B. J. Ghiya et al.331 synthesized some mercapto
pyrimidine derivatives (XI) and screened for their anticancer, antitubercular and anti
HIV activities. N. V. Kaplina and co-workers332 shows herpes inhibiting activity of
some mercapto pyrimidine derivatives (XII).

































Moreover, B. Chaudhari et al.333 prepared N6-(2-aminopyrimidin-4-yl)-
quinoline-4,6-diamine as N-type calcium channel antagonists for the treatment of
pain. E.Devi Sree and co-workers334 have prepared pyrimidine derivatives and tested
for antimicrobial activity. A. L Kovalenko.335 synthesized and reported antifungal
activity of pyrimidine derivatives. P. Shiv Singh and co-workers336 synthesized 4-(4-
pyrazolyl)-2-aminopyrimidines and tested them for their antimicrobial activity.
D.Michael Varney and co-workers337 have synthesized and evaluated 5-thia-
2,6-diamino-4 (3H)-oxopyrimidines (XIII) as potent inhibitors of Glycinamide























Paolo La Colla et al.338 have synthesized various 5-alkyl-2-(alkyl/cycloalkkyl
thio)-6-(2,6-dichloro/2,6-difluoro phenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones
(XIV) and tested as anti-HIV agents in both cell-based and enzyme (recombinant
reverse transcriptase)assay.


























V. Lather and co-workers339 have been proposed to predict the anti-HIV
activity of dihydro (alkylthio) (naphthylmethyl) oxopyrimidines (XV). These models
















J. L. Whittingham et al.340 have described pyrimidine ring as a platform for
antimalarial drug. G. Z. Han et al.341 documented the pyrimidine derivatives as
anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human
breast cancer. D. K. Tack et al.342 reported anthracycline vs nonanthracycline therapy
for breast cancer. P. Cano-Soldado et al.343 have described pyrimidine nucleus as an
inhibitors of HIV-1 reverse transcriptase. M. Gompel et al.344 have isolated
pyrimidine derivatives,a new family of protein kinase inhibitors from the ascidian
aplidium meridianum. Junmei Wang et al.345 have prepared pyrimidine (XVI) as HIV-
1 Reverse Transcriptase.










T. Shimizu co-workers346 have described N3-substituted pyridine and related
pyrimidine nucleosides as antinociceptive effects in mice. C. Sanmartin et al.347 have
prepared new symmetrical derivatives as cytotoxic agents and apoptosis inducers. A.
Agarwal et al.348 have synthesized 2,4,6-trisubstituted pyrimidine derivatives as
pregnancy interceptive agents.
S. Shigeta et al.349 have been synthesized 5-alkyl-2-thiopyrimidine nucleoside
analogues and examined for antiviral activities against Herps Simplex virus (HSV),
Varicella-Zoster virus (SZV) and Human Cytomegalo virus (HCMV).
Herve Ganeste and co-workers350 synthesized substituted 1H-pyrimidin-2-one























A. Mai et al.351 have synthesized 5-alkyl-2-alkylamino-6-(2,6-
difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad
spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO
family. I. Yamamoto et al.352 have reported some oxopyrimidines searching for the
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novel antagonist or agonist of barbiturates to the sleep mechanism based on the
uridine receptor. Y.L. Huang et al.353 have synthesized non classical antifolates, 5-
(Nphenylpyrrolidin – 3 – yl ) - 2, 4, 6 – triaminopyrimidinesand 2, 4 -diamino-6(5H)-
oxopyrimidinesas antitumor activity.
S. batra et al.354 have synthesized several 1-(2-cyano-3-aryl-allyl)-3-urea by
the reaction between allylamines generated from Baylis-Hilman acetates and
substituted isocyanates and isothiocyanate. Further, their cyclization in the presence
of a base led to the formation of 5-arylmethyl-4-imino-3-aryl-3,4-dihydro-1H-









2-(Arylcarbonylmethyl)thio-6-alpha-naphthylmethyl derivatives of dihydro
alkoxy benzyl oxopyrimidines355 (DABO) were newly found to exhibit activity
against both HIV-1 and HIV-2. The compounds were evaluated for their in vitro anti-
HIV activity in MT-4 cells.
Looking to the diversified activities exhibited and in continuation of our
research work on the synthesis of biologically active heterocycles, the synthesis and
biological screening of pyrimidine derivatives have been described as under.
SECTION-I :Synthesis and biological Screening of 4" -[2 -(4'-chlorophenyl
-6 - methylimidazo [ 1, 2 – a ] pyridin – 3 – yl ] - 6" – aryl - 2" -
aminopyrimidines.
SECTION-II :Synthesis and biological Screening of 6"-[2-(4'- chlorophenyl)
-6 - methylimidazo [ 1, 2 – a ] pyridine – 3-yl]- 4"-arylpyrimidin-
2"(1"H)-ones.
SECTION-III :Synthesis and biological Screening of 6"-[2-(4'- chlorophenyl)
-6-methyl imidazo [1, 2 – a ] pyridin-3-yl] - 4" - aryl pyrimidine-
2"- (1"H)-thiones.
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SECTION – I
SYNTHESIS AND BIOLOGICAL SCREENING OF 4" - [ 2 - (4'-
CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]-
6"-ARYL-2"-AMINOPYRIMIDINES.
Aminopyrimidines represent one of the most active classes of compounds
possessing a wide spectrum of biological activities, such as significant in vitro activity
against DNA and RNA viruses including polio viruses, diuretic, antitubercular
activity etc. These valid observation led us to synthesize 4" - [ 2 - (4'-chlorophenyl)-6-
methyl imidazo [1, 2-a] pyridin-3-yl]-6"-aryl-2"-aminopyrimidines of Type (VIII) by
cyclocondensation of 2-(4'-chlorophenyl)-6-methyl-3-[1"-aryl- 2"-propene-1"one-3-yl




















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I page no. 41
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IR SPECTRAL STUDY OF 4" - [ 2 - (4'-CHLOROPHENYL)-6-METHYL
IMIDAZO [ 1, 2 – a ] PYRIDIN – 3 – YL ] - 6"-(4'''-METHYLPHENYL)-2"-
AMINOPYRIMIDINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).




C-H str.(asym.) 2908 2990-2850 648
C-H str. (sym.) 2880 2880-2860 "
C-H def. (asym. 1450 1470-1430 "
Alkane
C-H def. (sym.) 1369 1395-1370 "
C-H str. 3058 3090-3030 "
C=C str 1450 1600-1450 "
Aromatic
C-H i.p. (def.) 1130 1300-1100 "
C=N str. 1630 1612-1593 649Imidazo[1,2-a]
pyridine C-N str. 1070 1220-1020 "
N-H str. (-NH2) 3265 3350-3250 "
C=N str. 1558 1612-1550 "
Pyrimidine
C-N str. 1186 1220-1020 "
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NMR SPECTRAL STUDY OF 4" - [ 2 - (4'-CHLOROPHENYL)-6-METHYL
IMIDAZO [1, 2-a] PYRIDIN -3-YL]- 6"-(4'''-METHYLPHENYL)-2"-
AMINOPYRIMIDINE.








1 2.20 3H Singlet Ar-CH3(j)
2 2.31 3H Singlet Ar-CH3(k)
3 4.19 2H Singlet Ar-NH2(i)
4 6.95 2H doublet Ar-H(f,h)
5 7.14 -7.16 2H doublet Ar-H(cc')
6 7.26-7.30 4H doublet Ar-H(aa',dd')
7 7.38-7.41 2H doublet Ar-H(bb')
8 7.69-7.68 1H singlet Ar-H(e)
9 8.09 1H Singlet Ar-H(g')
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SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF 6" - [ 2 - ( 4' -
CHLOROPHENYL)-6-METHYLIMIDAZO [1, 2-a] PYRIDIN-3-YL]- 4"-
ARYLPYRIMIDIN-2"(1"H)-ONES.
Looking to the interesting therapeutic activity of pyrimidinone ring system, It
was considered worthwile to synthesis compounds bearing pyrimidine liked to the
pyrimidinone nucleus. In the past years considerable evidence has been accumulated
to demonstrate the efficiency of pyrimidinones. The compounds of 6" - [ 2 - (4'-
chlorophenyl)-6-methylimidazo [1, 2-a] pyridin-3-yl]- 4"-arylpyrimidin-2"(1"H)-ones
of Type (IX) have been prepared by the condensation of 2-(4'-chlorophenyl)-6-
methyl-3-[1"-aryl- 2"-propene-1"-one-3-yl ]-imidazo[1,2-a]pyridine of Type (I) with



















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I page no. 41
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IR SPECTRAL STUDY OF 6" - [ 2 - (4'-CHLOROPHENYL)-6-
METHYLIMIDAZO [1, 2-a] PYRIDIN-3-YL] - 4" - ( 4''' – METHYLPHENYL )
PYRIMIDIN-2"-(1"H) ONE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2994 2990-2850 648
C-H str. (sym.) 2871 2880-2860 "
C-H def. (asym.) 1446 1470-1435 "
Alkane
C-H def. (sym.) 1377 1390-1370 "
C-H str. 3053 3090-3030 "
C=C str 1475 1450-1600 "
Aromatic
C-H i.p. (def.) 1197 1300-1100 "
Oxopyri. C=O str. 1677 1680-1652 649
C=N str. 1627 1630-1593 "Imidazo[1,2-a]
pyridine C-N str. 1128 1220-1020 "
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NMR SPECTRAL STUDY OF 6" - [ 2 - (4'-CHLOROPHENYL)-6-
METHYLIMIDAZO [1, 2-a] PYRIDIN-3-YL] - 4" - ( 4''' – METHYLPHENYL )
PYRIMIDIN-2"-(1"-H) ONE.








1 2.30 3H singlet Ar-CH3(j)
2 2.35 3H singlet Ar-CH3(k)
3 4.88 1H singlet Ar-H(h)
4 7.11-7.13 1H doublet Ar-H(f)
5 7.18 -7.20 2H doublet Ar-H(dd')
6 7.37-7.39 2H doublet Ar-H(aa')
7 7.41-7.43 2H doublet Ar-H(cc')
8 7.52-7.55 1H doublet Ar-H(e)
9 7.66-7.68 2H doublet Ar-H(bb')
10 7.83 1H singlet Ar-NH(i)
11 8.14 1H singlet Ar-H(g)
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MASS SPECTRAL STUDY OF 6" - [ 2 - (4'-CHLOROPHENYL)-6-METHYLIMIDAZO [1, 2-a] PYRIDIN-3-YL] - 4" - ( 4''' –
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 6" - [ 2 - (4'-
CHLOROPHENYL)-6-METHYLIMIDAZO [1, 2-a] PYRIDIN-3-YL]- 4"-
ARYLPYRIMIDIN-2"(1"H)-ONES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See(A), Part-I, Section-I (A),on page no. 37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'methylphenyl)-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no. 37
[D] Synthesis of 6" - [ 2 - (4'-chlorophenyl)-6-methylimidazo [1, 2-a]
pyridin-3- yl]- 4"-(4"'methylphenyl)pyrimidin-2"(1"H)-ones(9i).
A mixture of 2-(4'-chlorophenyl)-6-methyl-3-[1"-(4"'methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine (4.27gm, 0.01 mol) and urea (0.60gm,
0.01 mol) in ethanol (15 ml) was refluxed in presence of alcoholic KOH for 12 hrs.
The excess solvent was distilled out and the product was poured in to crused ice, the
separated solid was filtered out and crystallized from ethanol. Yield 65 %, m.p. 165oC
(C25H19ClN4O ; Required : C, 70.34; H, 4.49; N, 13.12%; found : C, 70.33; H, 4.45;
N, 13.11%;)
Similarly, other 6" - [ 2 - (4'-chlorophenyl)-6-methylimidazo [1, 2-a] pyridine
3- yl]- 4"-arylpyrimidin-2"(1"H)-ones. were prepared. The physical data are recorded
in Table No.9
[E] Biological Screening of of 6" - [ 2 - (4'-chlorophenyl)-6-methylimidazo [1,
2-a] pyridin- 3- yl]- 4"-aryl pyrimidin-2"(1"H)-ones.
Biological Screening were carried out as described in Part-I, Section-1 page
no.38 The zones of inhebition of test solution are recorded in Graphical Chart no-9.
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TABLE NO. 9 PHYSICAL COSTANTS OF 6" - [ 2 - (4'-CHLOROPHENYL)-6-METHYLIMIDAZO [1, 2-a] PYRIDIN-3-YL] - 4" –
(ARYL ) PYRIMIDIN-2"-(1"H)- ONES.





9a C6H5- C24H17ClN4O 412.5 189 60 13.57 13.56
9b 3-Cl-C6H4 - C24H16Cl2N4O 447.0 168 68 12.53 12.51
9c 4-Cl-C6H4 - C24H16Cl2N4O 447.0 155 74 12.53 12.51
9d 2-4-(Cl)2-C6H3- C24H15Cl3N4O 481.5 190 55 11.63 11.60
9e 4 -F-C6H4- C24H16ClFN4O 430.5 183 59 13.00 13.00
9f 4-Br-C6H4- C24H16BrClN4O 491.5 192 66 11.39 11.35
9g 4 -OH-C6H4- C24H17ClN4O2 428.5 170 63 13.06 13.03
9h 4-NH2-C6H4- C24H18ClN5O 427.5 205 70 16.37 16.35
9i 4-CH3-C6H4- C25H19ClN4O 426.5 165 65 13.12 13.11
9j 4-OCH3-C6H4- C25H19ClN4O2 442.5 198 56 12.65 12.63
9k 3-NO2-C6H4- C24H16ClN5O3 457.5 166 67 15.30 15.28
9l 4-NO2-C6H4- C24H16ClN5O3 457.5 174 60 15.30 15.27
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GRAPHICAL CHART NO. 9: BIOLOGICAL SCREENING OF 6" - [ 2 - (4'-CHLOROPHENYL)-6-METHYLIMIDAZO [1, 2-a]






















B.mega 15 22 15 16 21 14 17 17 15 22 13 16 22 22 22 0 0
S.aureus 12 19 16 15 14 20 18 12 14 22 15 23 19 23 22 0 0
E.coli 23 17 15 20 16 14 23 22 16 16 17 15 19 22 24 0 0
S. typhi 17 19 16 14 13 21 15 17 21 24 16 17 22 25 23 0 0
A.niger 22 17 18 22 18 14 15 16 15 22 18 19 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-V
SECTION – II: BIOLOGICAL SCREENING OF 6" - [ 2 - (4'-CHLOROPHENYL)-6-METHYLIMIDAZO [1, 2-a] PYRIDIN-3-YL] –
4" – (ARYL) PYRIMIDIN-2"-(1"H)- ONES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E. coli S. typhi A. niger
9b-(22) 9b-(19) 9a-(23) 9f-(21) 9a-(22)
9e-(21) 9f-(20) 9d-(20) 9i-(21) 9d-(22)
9j- (22) 9j-(22) 9g-(23) 9j-(24) 9j-(22)
9l-(23) 9h-(22)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
Greseofulvin (50 µg) -- -- -- -- 22
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SECTION-III
SYNTHESIS AND BIOLOGICAL SCREENING OF 6"-[2 -(4' -
CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]- 4"-
ARYL PYRIMIDINE-2"-(1"H)-THIONES
Compounds containing pyrimidine ring are widely available in nature. Many
thio pyrimidine derivatives are reported to possess different therapeutic activities. In
view of these findings, it was considered worthwhile to synthesize some new 6"
-[2-( 4'-chlorophenyl)-6-methyl imidazo [1, 2-a] pyridin-3-yl]- 4"-aryl pyrimidine-2"-
(1"H)-thiones of Type (X) have been prepared by the reaction of 2-(4'-chlorophenyl)-
6-methyl-3-[1"-aryl- 2"-propene-1"-one-3-yl ]-imidazo[1,2-a]pyridine of Type (I)



















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I page no. 41
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IR SPECTRAL STUDY OF 6" - [ 2 - ( 4'-CHLOROPHENYL)-6-METHYL
IMIDAZO [1, 2-a] PYRIDIN-3-YL]- 4"-(4'''-METHYLPHENYL)
PYRIMIDINE-2"-(1"H)-THIONE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
Mode Observd Reported
Ref.
C-H str.(asym.) 2931 2990-2850 648
C-H str. (sym.) 2880 2880-2860 "
C-H def. (asym. 1460 1470-1435 "
Alkane
C-H def. (sym.) 1371 1390-1370 "
C-H str. 3060 3090-3030 "
C=C str 1492 1450-1600 649
Aromatic
C-H i.p. (def.) 1172 1300-1100 "
Thiopyri. C=S str. 1158 1590-1550 "
C=N str. 1598 1630-1593Imidazo[1,2-a]
pyridine C-N str. 1080 1220-1020 "
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NMR SPECTRAL STUDY OF 6" - [ 2 - ( 4'-CHLOROPHENYL)-6-METHYL
IMIDAZO [1, 2-a] PYRIDIN-3-YL]- 4"-(4'''-METHYLPHENYL)
PYRIMIDINE-2"-(1"H)-THIONE.








1 2.33 3H singlet Ar-CH3(j)
2 2.36 3H singlet Ar-CH3(k)
3 4.97 1H singlet Ar-H(h)
4 7.13-7.15 1H doublet Ar-H(f)
5 7.19 -7.21 2H doublet Ar-H(aa')
6 7.33-7.35 2H doublet Ar-H(cc')
7 7.41-7.43 2H doublet Ar-H(bb')
8 7.54-7.56 1H doublet Ar-H(e)
9 7.68-7.70 2H doublet Ar-H(dd')
10 8.06 1H singlet Ar-NH(g)
11 8.75 1H singlet Ar-H(i)
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EXPERIMENTALS
SYNTHESIS AND BIOLOGICAL SCREENING OF 6" - [ 2 - ( 4'-
CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]- 4"-
ARYL PYRIMIDINE-2"-(1"H)-THIONES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde.
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'- methylphenyl)-
2"-propene-1"one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no.37
[D] Synthesis of 6" - [ 2 - ( 4'-chlorophenyl)-6-methyl imidazo [1, 2-a]
pyridin-3-yl]- 4"-(4"'methylphenyl) pyrimidine-2"-(1"H)-thiones(10i).
A mixture of 2-(4'-chlorophenyl)-6-methyl-3-[1"-(4"'methylphenyl)- 2"-prop-
en-1"ones-3-yl ]-imidazo [1,2-a]pyridine (4.27gm, 0.01 mol) and thiourea (0.60gm,
0.01 mol) in ethanol (20 ml) was refluxed in presence of alcoholic KOH for 12 hr.
The excess solvent was distilled out and the residue was poured in to crused ice, the
separated solid was filtered out and crystallized from ethanol. Yield 68 %, m.p. 170oC
(C25H19ClN4S ; Required : C, 67.79; H, 4.32; N, 12.65 %; found : C, 67.77; H,
4.30; N, 12.63 %;)
Similarly, other of 6" - [ 2 - ( 4'-chlorophenyl)-6-methyl imidazo [1, 2-a]
pyridin-3-yl]- 4"-aryl pyrimidine-2"-(1"H)-thiones . were prepared. The physical data
are recorded in Table No.10
[E] Biological Screening of of 6" - [ 2 - ( 4'-chlorophenyl)-6-methyl imidazo
[1, 2-a] pyridin-3-yl]- 4"-aryl pyrimidine-2"-(1"H)-thiones.
Biological Screening were carried out as described in Part-I, Section-1.page
no. 38 The zones of inhebition of test solution are recorded in Graphical Chart No.10
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TABLE NO. 10 PHYSICAL COSTANTS OF 6" - [ 2 - ( 4'-CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-YL]- 4"-
(ARYL) PYRIMIDINE-2"-(1"H)-THIONES.





10a C6H5- C24H17ClN4S 428.5 195 79 13.06 13.05
10b 3-Cl-C6H4 - C24H16Cl2N4S 463.0 188 68 12.09 12.07
10c 4-Cl-C6H4 - C24H16Cl2N4S 463.0 175 59 12.09 12.08
10d 2-4-(Cl)2-C6H3- C24H15Cl3N4S 497.5 165 72 11.25 11.23
10e 4 -F-C6H4- C24H16ClFN4S 446.5 178 66 12.54 12.51
10f 4-Br-C6H4- C24H16BrClN4S 507.5 190 55 11.03 11.01
10g 4 -OH-C6H4- C24H17ClN4OS 444.5 200 70 12.59 12.56
10h 4-NH2-C6H4- C24H18ClN5S 443.5 168 62 15.78 15.77
10i 4-CH3-C6H4- C25H19ClN4S 442.5 170 68 12.65 12.64
10j 4-OCH3-C6H4- C25H19ClN4OS 458.5 177 63 12.21 12.20
10k 3-NO2-C6H4- C24H16ClN5O2S 473.5 160 58 14.78 14.76
10l 4-NO2-C6H4- C24H16ClN5O2S 473.5 180 64 14.78 14.75
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B.mega 19 21 17 19 15 20 19 21 12 17 22 12 22 22 22 0 0
S.aureus 16 19 14 15 22 17 15 23 14 13 20 13 19 23 22 0 0
E.coli 18 16 14 17 19 16 16 22 17 14 24 17 19 22 24 0 0
S. typhi 19 22 12 20 14 18 17 18 19 22 23 16 22 25 23 0 0
A.niger 17 19 16 18 18 19 21 21 19 18 17 16 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-V
SECTION – III : BIOLOGICAL SCREENING OF 6" - [ 2 - ( 4'-CHLOROPHENYL)-6-METHYL IMIDAZO [1, 2-a] PYRIDIN-3-
YL]- 4"-(ARYL) PYRIMIDINE-2"-(1"H)-THIONES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
10b-(21) 10b-(19) 10a-(18) 10b-(22) 10g-(21)
10f-(20) 10e-(22) 10e-(19) 10i-(20) 10h-(21)
10h-(21) 10h-(23) 10h-(22) 10j-(22)
10k-(22) 10k-(20) 10k-(24) 10k-(23)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --










Isoxazole is a five membered heterocyclic compound having two hetero atom:
oxygen at position 1 and nitrogen at position 2. In 1888, Claisen first reported an
isoxazole (I) for a product from the reaction of 1,3 diketone with hydroxylamine.356
Subsequently a solid foundation for the chemistry of isoxazole was laid down by
Claisen and his students. It was shown to possess typical properties of an aromatic
system but under certain reaction conditions. Particularly in reducing or basic media,








The next important contribution to the chemistry of isoxazoles was made by
A. Quelico357 in 1945, when he begane to study the formation of isoxazoles from
nitrile N-oxide and unsaturated compounds.
SYNTHETIC ASPECT
1. L.S.Crawley and W.J.Fanshawe358 were prepared isoxazole from











2. Dawood Kamal et al359 have prepared isoxazole derivatives from enamino
nitriles
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3. V.B.Tayade et al 360 synthesized some new 3,5-diarylisoxazoles from the
reaction of 2-aryl acetophenones with hydroxyl amine hydrochloride in
presence of alkali.
4. Solid phase synthesis of isoxazole derivatives based on aminoacids was
reported by Lidia De Luca and co-workers361 in the presence of basic catalyst
and dichloro methane used as a solvent. One-Pot synthesis of
polyfunctionalized isoxazoles362 have been prepared by the reaction of
dipyrrolidinium 3,3-dimethylpentanedinitrile -2,4-dinitronate and acetyl
chloride in benzene.
5. A variety of 3,5-disubstituted 4-bromoisoxazoles363-365 were prepared in good











6. Keisuke Suzuki et al366 have synthesized functionalized isoxazole derivatives














7. Mark Lautens and Ame´lie Roy367 have constructed isoxazoles , were
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P. M. Welsing et al.392 have documented the isoxazoles as tumornecrosis
factor blocking agents and leflunomide for treating rheumatoid arthritis in the
Netherlands.
S. J. Bingham et al.393have synthesized isoxazole derivatives as an antiuclear
agents.M. R Barbachyn et al.394 have described the phenylisoxazolines as novel and
viable antibacterial agents active against Gram-positive pathogens.
Stefano Chimichi and co-workers395 have investigated cytotoxic activity of 3-
quinolinoyl isoxazoles (II) against leukemia and adenocarcinoma derived cell lines in
comparison to the normal human keratinocytes. Novel cyclohexyl drug resistance
























T. D. Aicher et al.397 reported isoxazoles (IV) as hypoglycemic agents. M.
Masui et al.398 have prepared isoxazoles having pesticidal activity. Some excellent
herbicidal results obtained by K.V. Reddy et al.399C. B. Xue et al.400 have reported an
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Julia Kaffy et al.401 have been synthesized various five membered heterocycles
with oxygen and nitrogen atoms. The 4,5-diarylisoxazole (V) exhibited greater
antitubulin activity, but modest antiproliferative activity. Kai Fan Cheng402 have been
synthesized 3-(4-hydroxyphenyl)-4,5-dihydro-5-aceticacidmethylester isoxazole, an
inhibitor of the proinflammatory cytokine MIF, two critical modifications and chiral
resolution have significantly improved the potency of the inhibition.Compound (VI)































Moreover, S. Rung and D. Dus403 have synthesized some new isoxazoles as
remedy for leukemia. M. Scobie and co-workers404 have prepared isoxazole
derivatives and studied their antitumor activity. G. Daidone et al.405 synthesized 3-
(isoxazol- 3-yl)-quinazolin-4-(3H)-one derivative and tested for their analgesic and
antiinflammatory activities as well as for their acute toxicity and ulcerogeniceffect.
M. W. Salter et al.406 have prepared some isoxazole as cellular neuroplasticity
mechanisms mediating pain persistence. M. Matringe et al.407 have reported some new
p-hydroxyphenylpyruvate dioxygenase inhibitor resistant plants. D. R. Mehlisch et
al.408 have synthesized isoxazole derivative as analgesic efficacy of intramuscular
parecoxib sodium in postoperative dental pain. W. A. Ray et al.409 have reported
isoxazole derivative as cardiovascular toxicity of valdecoxib.
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With an intension of preparing the compounds possessing better therapeutic
activity, we have under taken the preparation of isoxazoles bearing imidazo[1,2-
a]pyridine nucleus which have been described as follows.
SECTION I : SYNTHESIS AND BIOLOGICAL SCREENING OF 2 - ( 4' -
CHLOROPHENYL)-6-METHYL- 3-(3"-ARYL ISOXAZOL-5"-
YL) IMIDAZO [1, 2-a] PYRIDINES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL- 3-(3"-ARYL ISOXAZOL-5"-YL) IMIDAZO [1, 2-a] PYRIDINES.
Isoxazoles have been reported to have various pharmacological activities like
antibacterial, antifungal, insecticidal etc. In order to achieving better drug potency, we
have prepared isoxazole derivatives of Type (XI) by the cyclocondensation of 2-(4'-
chlorophenyl)-6-methyl-3-[1"-aryl- 2"-propene-1"-one-3-yl ]-imidazo[1,2-a]pyridine
















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC,
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I ,Page No. 41
Vipul Bhuva, Ph.D. Thesis Study on Isoxazoles
174
IR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-(3"-
(4'''-METHYLPHENYL) ISOXAZOL-5"-YL) IMIDAZO [1, 2-a] PYRIDINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2960 2990-2850 648
C-H str. (sym.) 2860 2880-2860 "
C-H def. (asym.) 1469 1470-1435 "
Alkane
C-H def. (sym.) 1377 1390-1370 "
C-H str. 3055 3090-3030 649
C=C str 1500 1600-1450 "
Aromatic
C-H i.p. (def.) 1199 1300-1100 "
C=C str 1633 1680-1550 "
C=N str 1579 1690-1460 "
Isoxazole
N-O str. 821 850-810 "
C-N str. 1099 1220-1020 "Imidazo[1,2-a]
pyridine C=N str. 1608 1612-1593 "








Vipul Bhuva, Ph.D. Thesis Study on Isoxazoles
175
NMR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-(3"-
(4'''-METHYLPHENYL) ISOXAZOL-5"-YL) IMIDAZO [1, 2-a] PYRIDINE.








1 2.26 3H Singlet Ar-CH3(j)
2 2.49 3H Singlet Ar-CH3(i)
3 7.17-7.20 1H doublet Ar-H(f)
4 7.24-7.29 3H Quatret Ar-H(cc',h)
5 7.35-7.38 3H Quartet Ar-H(bb,e')
6 7.40-7.44 2H doublet Ar-H(aa')
7 7.52-7.56 2H doublet Ar-H(dd')
8 8.32 1H singlet Ar-H(g)
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MASS SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-(3"-(4'''-METHYLPHENYL) ISOXAZOL-5"-YL)































































































Reflux 4 hrs.Reflux 4 hrs.
CHCl3
Reflux 6 hrsReflux 6 hrs
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL- 3-(3"-ARYL ISOXAZOL-5"-YL) IMIDAZO [1, 2-a] PYRIDINES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no. 37
[D] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[3"-(4"'-methylphenyl)
isoxazol-5"-yl] imidazo [1, 2-a] pyridines(11i).
A mixture of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine (3.93 gm, 0.01 mol) in ethanol (50 ml),
and hydroxylamine hydrochloride (0.59 gm, 0.01 mol) were added. The reaction
mixture was refluxed on oil bath for 10 hrs. The product was isolated and crystallized
from ethanol. Yield 54 %, m.p. 156oC.
(C24H18ClN3O ; Required : C, 72.09; H, 4.54; N, 10.51%; found : C, 72.07; H, 4.52;
N, 10.49%)
Similarly,other 2-(4'-chlorophenyl)-6-methyl- 3-(3"-aryl isoxazol-5"-yl)
imidazo [1, 2-a] pyridines. were prepared. The physical data are recorded in Table
No.11.
[C] Biological Screening of 2-(4'-chlorophenyl)-6-methyl- 3-(3"-aryl isoxazol-
5"-yl) imidazo [1, 2-a] pyridines.
Biological Screening were carried out as described in Part-I Section-1 page
no.38. .The zones of inhibition of test solution are recorded in Graphical Chart No 11.
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TABLE NO. 11 PHYSICAL CONSTANTS OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-[(3"-(ARYL) ISOXAZOL-5"-YL)]
IMIDAZO [1, 2-a] PYRIDINES.





11a C6H5- C22H16ClN3O 385.5 180 71 10.89 10.86
11b 3-Cl-C6H4 - C23H15Cl2N3O 420.0 174 65 10.00 9.98
11c 4-Cl-C6H4 - C23H15Cl2N3O 420.0 168 68 10.00 9.98
11d 2-4-(Cl)2-C6H3- C23H14Cl3N3O 454.5 165 59 9.24 9.22
11e 4 -F-C6H4- C23H15ClFN3O 403.5 152 63 10.41 10.39
11f 4-Br-C6H4- C23H15BrClN3O 464.5 192 72 9.04 9.01
11g 4 -OH-C6H4- C23H16ClN3O2 401.5 185 60 10.46 10.44
11h 4-NH2-C6H4 C23H17ClN4O 400.5 180 55 13.98 13.95
11i 4-CH3-C6H4- C24H18ClN3O 399.5 156 54 10.51 10.49
11j 4-OCH3-C6H4- C24H18ClN3O2 415.5 185 60 10.10 10.07
11k 3-NO2-C6H4- C23H15ClN4O3 430.5 195 51 13.00 12.97
11l 4-NO2-C6H4- C23H15ClN4O3 430.5 190 52 13.00 12.97
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GRAPHICAL CHART NO. 11 : BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-(3"-ARYL -ISOXAZOL-






















B.mega 13 22 13 18 16 21 15 16 14 20 12 14 22 22 22 0 0
S.aureus 16 20 14 23 15 12 15 21 16 15 21 14 19 23 22 0 0
E.coli 17 21 16 16 13 12 21 17 22 16 20 16 19 22 24 0 0
S. typhi 22 18 18 21 12 15 16 15 17 20 16 18 22 25 23 0 0
A.niger 18 22 19 15 14 16 21 12 19 17 15 22 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-VI
SECTION – I: BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-6-METHYL- 3-(3"-ARYL -ISOXAZOL-5"-YL) IMIDAZO
[1, 2-a] PYRIDINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
11b-(22) 11b-(20) 11b-(21) 11a-(22) 11b-(22)
11f-(21) 11d-(23) 11g-(21) 11d-(21) 11g-(21)
11j-(20) 11h-(21) 11i- (22) 11j-(20) 11l- (22)
11k-(21) 11k-(20)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --










Barbitones, which belongs to an important group of nitrogen containing
heterocyclic compounds have been extensively explored for their application in the field
of medicine. Most important is the effect of barbiturates on CNS. Barbituric aicd
derivatives constitute an important class of compounds possessing diverse type of
biological properties including hyphotic, sedative, anticonvulsant,cardiovascular etc.
Barbituric acid usually represented as the trione was first made about 1864 and it has no
hypnotic properties. The origin of the name is lost, although there are several plausible
explanations associated with St. Barbara's feast day, a favourite Munchen Kellnerin











Different methods are used for the preparation of barbitones in literature410, 411










+ gla. acetic acid
2. Cao-Yan Weu et. al.413 have prepared barbitones by reaction of different aldehydes
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3. Ogus Funda et. al.414 have prepared barbitones by the reaction of acetone and
barbituric aicd.
THERAPEUTIC IMPORTANCE
The first hyphotic barbiturate, 5,5-diethyl barbituric acid (barbital, Veronal ; I;
R1R2=Et) was made in 1904, was introduced into medicine in 1905, and is still used
sometimes; the second was 5-ethyl-5-phenylbarbituric acid (phenobarbital, Luminal, I;
R1=Et, R2=Ph), also prepared in 1904 but used as a long acting CNS depressant only
from 1912 until the present day. Several thousand active barbiturates were made
subsequently but scarcely a dozen are still used to any extent. Among these are
pentobarbital (Nembutal; I; R1=C2H5, R2=CHMePr), amobarbital (Amytal ; I; R1=C2H5 ,
R2=CH2CH2CHMe2),secobarbital (Seconal; I; R1=CH2 CH=CH2, R2=CHMePr),


































The 'pseudo-barbiturate', 2-methyl-3-o-tolylquinazolin-4(3H)-one (methaqualone,
Revonal; IV) has an ever winder spectrum of activities that do the barbiturates proper; it
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appears to be quite widely used as a sedative, hyphotic, anticonvulsant, antispasmodic
and local anaesthetic agent418.
Some barbituric acid derivatives used as sedative and hyphotic iscarbubarb419,
which is used as veternary anaesthetics. Some isoxazolo pyrimidines have been studied
because of their potential as pesticidal420,421 activity. Some barbiturates showing
cardiovascular422-424 and analgesics and antiinflammatory activities425 have been reported.
Some isoxazolopyrimidines have been extensively studied and reported as antagonist426
and antitumor427 activity. Wolf-Gang et. al.428 have reported 5-(3-Benzylthiazolidin-2-
ylidene)-1,3-dimethyl hexahydropyrimidin-2,4,6-trione having agricultural activity.
Andre Roland et. al.429 demonstrated some barbituric acid derivatives used as herbicidal
and insecticides.
M. T.Omar 430 has synthesised barbitone derivatives, showing antimicrobial
activity. Sakai et. al.431 have synthesised new barbitones which were assessed for bone
and cartilage disease. Ambrogio Oliva et. al.432 have synthesized barbitones possessing
antimetastatic and antitumor activity. W. Weber et. al.433 have synthesised barbitones as
main metabolite (V). Frank Grams et. al.434 have synthesised barbitones and found to be



















Ulf Wellmar et. al.436 have synthesised some uracil derivatives and screened for
antiviral activity437,438. Raymond et. al.439 have synthesized some barbiturates (VII),
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which showed anticancer activity. M. R. Mahmoud et. al.440 synthesised barbituric acid















D. L. Levesque et. al.441 have synthesised barbitones as uridine phosphoralase
inhibitors. I. M Wyzlic. et. al.442 have synthesised and tested barbitones as anticonvulsant
agent. A. N. Shivanyuk and co-worker443 have prepared barbitones as Porphyrin
Melamine Calixarene receptor. Gursu Esin et. al.444 have prepared barbitone as biological
























( III) (I )
1, 2 , l , 3 3, t,
S. G. Abdel Hamide et. al.446 have prepared barbitone as anticonvulsant agent
(IX). Li Laizhong et. al. 447 have synthesised barbitones and screened for their
anticonvulsant activity.
Recently, Geppert Dangmar et. al.448 have synthesised barbitones and tested their
metalloproteinase inhibitory activity.
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These observations led us to explore barbitone chemistry by synthesizing its derivatives
in order to achieve better therapeutic agents. It has been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL SCREENING OF 2 - [ ( 4' -
CHLOROPHENYL) – 6 - METHYL IMIDAZO [1,2-a] PYRIDIN-3-
YL ] - ( 1" – PROPENE - 3" – ARYL - 3" – YL ) - PYRIMIDINE -
2"',4"',6"'-(3"'H, 5"'H)-TRIONES.
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING 2-[(4'-CHLOROPHENYL)-6-
METHYL IMIDAZO [1,2-a] PYRIDIN-3-YL]-(1"-PROPENE-3"-ARYL-3"-YL)-
PYRIMIDINE- 2"',4"',6"'-(3"'H, 5"'H)-TRIONES.
Barbiturates derivatives possess good therapeutic activity in the field of
medicinal chemistry, Prompted by these facts, the preparation of 2-[(4'-chlorophenyl)-6-
methyl imidazo [1,2-a] pyridin-3-yl]-(1"-propene-3"-aryl-3"-yl)- pyrimidine- 2"',4"',6"'-
(3"'H, 5"'H)-triones. of type (XII) have been synthesised by the reaction with chalcone of





















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard drugs.
The details have been cited in part-I,section-I Page no. 41
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IR SPECTRAL STUDY OF 2-[(4'-CHLOROPHENYL)-6-METHYL
IMIDAZO[1,2-a] PYRIDIN-3-YL]-(1"-PROPENE-3"-(4''''-METHYLPHENYL)
-3"-YL)- PYRIMIDINE- 2"',4"',6"'-(3"'H, 5"'H)-TRIONE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range: 4000-
400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2887 2990-2850 648
C-H str. (sym.) 2877 2880-2860 "
C-H def. (asym.) 1440 1470-1430 "
Alkane
C-H def. (sym.) 1394 1395-1370 "
C-H str. 3056 3090-3030 "
C=C str 1537 1600-1450 "
Aromatic
C-H i.p. (def.) 1296 1300-1100 649
C=N str. 1600 1612-1593 "Imidazo[1,2-a]
pyridine C-N str. 1070 1220-1020 "
N-H str. 3350 3350-3250 "
C=O 1712 1750-1610 "
C=O 1730 1750-1610 "
Barbitones
C-H str.(asym.) 2950 2950-2850 "












Vipul Bhuva, Ph.D. Thesis Study on Barbitones
191
NMR SPECTRAL STUDY OF 2-[(4'-CHLOROPHENYL)-6-METHYL
IMIDAZO[1,2-a] PYRIDIN-3-YL]-(1"-PROPENE-3"-(4''''-METHYLPHENYL)
-3"-YL)- PYRIMIDINE- 2"',4"',6"'-(3"'H, 5"'H)-TRIONE.








1 2.30 3H singlet Ar-CH3(h)
2 2.40 3H singlet Ar-CH3(i)
3 6.95-6.99 1H doublet Ar-H(j)
4 7.14-7.18 2H doublet Ar-H(f,k)
5 7.20-7.29 4H multiplet Ar-H(cc',dd’)
6 7.35-7.46 3H doublet Ar-H (bb’,e)
7 7.60-7.63 2H doublet Ar-H(aa')
8 8.09 1H singlet Ar-H(g)














MASS SPECTRAL STUDY OF 2-[(4'-CHLOROPHENYL)-6-METHYL IMIDAZO[1,2-a] PYRIDIN-3-YL]-(1"-PROPENE-
3"-(4''''-METHYLPHENYL)-3"-YL)- PYRIMIDINE- 2"',4"',6"'-(3"’H, 5"’H)-TRIONE.












































































































Reflux 4 hrs. Reflux 4 hrs.
CHCl3
Reflux 6 hrs Reflux 6 hrs
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EXPERIMENTAL
SYNTHESIS AND BIOLOGOCAL SCREENING OF 2-[(4'-CHLOROPHENYL)-
6-METHYL IMIDAZO [1,2-a] PYRIDIN-3-YL]-(1"-PROPENE-3"-ARYL-3"-YL)-
PYRIMIDINE 2"',4"',6"'-(3"'H, 5"'H)-TRIONES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I,on page no. 37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)- 2"-
propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no. 37
[D] Synthesis of 2-[(4'-chlorophenyl)-6-methyl imidazo [1,2-a] pyridin-3-yl]-
(1"-propene-3"-(4"''-methylphenyl)-3"-yl)-pyrimidine- 2"’,4"’,6"’(3"’H,
5"'-H)-triones(12i).
A mixture of 2-(4'-chlorophenyl)-6-methyl-3-[1"-(4"'-methylphenyl)- 2"-propene-
1"-one-3-yl ]-imidazo [1,2-a]pyridine (3.8 g, 0.01 mol), barbituric acid (1.28 g, 0.01 mol)
in glacial acetic acid was refluxed for 10 hrs. in oil bath. The contents were poured in to
ice and product was isolated, crystallized from DMF. Yield, 69%, m.p.170oC.
(C28H21ClN4O3 ; Required : C, 67.67; H, 4.26; N, 11.27%; found : C, 67.65; H, 4.25; N,
11.25%; )
Similarly other barbitones have been prepared. The physical data are recorded in
Table No. 12
[E] ] Biological Screening of 2-[(4'-chlorophenyl)-6-methyl imidazo [1,2-a]
pyridin-3-yl]-(1"-propene-3"-aryl-3"-yl)- pyrimidine- 2"',4"',6"'-(3"'H,
5"'H)-triones .
Biological Screening was carried out as described in Part-I, Section-I
Page no.38 The zone for inhibition of the test solutions are recorded in Graphical Chart
No. 12
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TABLE NO. 12 PHYSICAL CONSTANTS OF 2-[(4'-CHLOROPHENYL)-6-METHYLIMIDAZO [1,2-a] PYRIDIN-3-YL]-
(1"- PROPENE-3"-ARYL-3"-YL)- PYRIMIDINE- 2"',4"',6"'-(3"'H, 5"'H)-TRIONES.
%of Nitrogen
Sr.No.





12a C6H5- C27H19ClN4O3 482.5 165 67 11.60 11.58
12b 3-Cl-C6H4 - C27H18Cl2N4O3 517.0 195 55 10.83 10.81
12c 4-Cl-C6H4 - C27H18Cl2N4O3 517.0 155 59 10.83 10.80
12d 2-4-(Cl)2-C6H3- C27H17Cl3N4O3 551.5 205 70 10.15 10.12
12e 4 -F-C6H4- C27H18ClFN4O3 500.5 190 65 11.19 11.17
12f 4-Br-C6H4- C27H18BrClN4O3 561.5 167 69 9.97 9.96
12g 4 -OH-C6H4- C27H19ClN4O4 498.5 158 72 11.23 11.21
12h 4-NH2-C6H4- C27H20ClN5O3 497.5 165 57 14.06 14.04
12i 4-CH3-C6H4- C28H21ClN4O3 496.5 170 69 11.27 11.25
12j 4-OCH3-C6H4- C28H21ClN4O4 512.5 200 75 10.92 10.90
12k 3-NO2-C6H4- C27H18ClN5O5 527.5 165 64 13.27 13.24
12l 4-NO2-C6H4- C27H18ClN5O5 527.5 177 50 13.27 13.25
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GRAPHICAL CHART NO. 12: BIOLOGICAL SCREENING OF 2 - [ ( 4' – CHLOROPHENYL ) – 6 - METHYLIMIDAZO






















B.mega 14 16 15 18 20 12 21 20 14 17 14 13 22 22 22 0 0
S.aureus 19 14 14 16 20 16 14 18 16 20 19 20 19 23 22 0 0
E.coli 18 16 18 21 17 13 12 19 16 21 18 17 19 22 24 0 0
S. typhi 17 20 17 20 20 21 14 16 18 16 13 15 22 25 23 0 0
A.niger 18 16 13 20 16 22 19 18 11 12 21 13 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-VII
SECTION – I: BIOLOGICAL SCREENING OF 2-[(4'-CHLOROPHENYL)-6-METHYL IMIDAZO [1,2-a] PYRIDIN-3-
YL]-(1"- PROPENE-3"-ARYL-3"-YL)- PYRIMIDINE- 2"',4"',6"'-(3"'H, 5"'H)-TRIONES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
12e-(20) 12a-(19) 12a-(18) 12b-(20) 12d-(20)
12g-(21) 12e-(20) 12c-(18) 12d-(20) 12f- (22)
12h-(20) 12k-(19) 12d- (21) 12e-(20) 12k-(21)
12l-(20) 12h-(19) 12f-(21)
12j-(21)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --










The five membered heterocyclic ring system 5-oxo-imidazolines have two





The discovery of the 2-substituted-5-imidazolines dates back to the year 1888,
when A. W. Hoffman449 for the first time discovered 5-oxo-imidazoline by heating N-
diacetylethylene diamine in a stream of dry hydrogen chloride. Moreover, some
compounds were prepared by A. Ladenburg450 by the fusion of two equivalents of
sodium acetate with one equivalent of ethylene diamine dihydrochloride.
SYNTHETIC ASPECT
Various methods have been reported for the synthesis of imidazolinones in
Literature451. Aminolysis of oxazolone with amine leads to the formation of
imidazolinones which has been reported in literature452.
1. Feng-Jun-Cai et. al.453 have synthesised 5-imidazolinone derivatives by micro-
waves irradiation.

















3. H.A. Allimony et. al.455 have synthesised new imidazolinone derivatives by
conventional method.
Vipul Bhuva, Ph.D. Thesis Study on 5-OXO-Imidazolines
201
MECHANISM
Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylamino acryclic acids obtained from the




















R' -NH2 ,Dry C5H5N / Abs.C2H5OH,K2CO3
The ring closer can be effected under a variety of conditions. Substituted
anilides have been converted to imidazolinone derivatives by the action of POCl3.
THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and
tolazoline and phenotolamine as adrenergic blocking agents. Various imidazolinones
are known to exhibit a broad spectrum of biological activities such as,
1. Antitubercular456









11. Sedative and hypnotics470
12. Bactericidal471, 472
13. Fungicidal473, 474







F. C. Geoffrey et. al 482 and B. L. Pilkington et. Al483 have synthesised and
studied antifungal activity of imidazolinones. L. J. Peter and Co-worker484 have
prepared substituted imidazolinones which inhibited the abnormal cell growth in
human body. S. Lauter and Co-worker485 have isolated imidazoline from different
methods and tested for the treatment of cytokine release. Imidazoline derivatives have
been prepared by Erick and co-worker486 showing anti-HIV activity. Ding Ming-Wu
et. Al487 have prepared novel imidazolines and reported their antifungal activity.
K. Vishnu et. al.488 has reported anti-AIDS, antibacterial and fungicidal
activity of 5-oxo-imidazolines. B. R. Shah and co-worker489 have prepared some new




















R2( III )( II )
V. Akyoshi et. al.490 have prepared some new imidazolinone derivatives (II)
and reported their herbicidal activity. Agrochemical activity of imidazolinones has
been reported by J. P. Bascou and co-workers491.
R. Sharma and co-workers492 have reported antimicrobial activity of 5-oxo-
imidazolines (III). K. K. Awasthi et. al.493 (IV) have synthesised some new
imidazolinone derivatives and reported their antimicrobial activity.










CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh et. Al494 have synthesised imidazolinones bearing thiazole as
moderately active bactericidal and fungicidal. H. H. Parekh et. Al495 have elaborated
better activity for some imidazolinones with activated benzylidene group at 5-
position.
D. M. Purohit et al496 synthesized 5-oxo-imidazoline (V) derivatives in
“Fluchloralin” moiety. D. M. Purohit et al497, 498 have synthesized 5-oxo-imidazolines
(VI) in “dichlorine” nucleus. D. M. Purohit et al 499 have synthesized 5-oxo-



























V. N. Patoliya et al 500, 501 have synthesized 5-oxo-imidazolines (VIII, IX)
evaluated its antimicrobial activity.



















( VIII ) ( IX )
A. R. Parikh et. al. have synthesized imidazolinones bearing phthalazine502, 2-
base of chloramphenicol503 moiety at one position which were evaluated for their
antimicrobial activity. A. R. Parikh et. al. 504 have reported 4-(4'-Arylidine-2'- phenyl-
5'-oxo-imidazolin-1-yl) benzophenones which were screened for their antimicrobial
activity. Biplabde et. al. 505 have reported some new 5-oxoimidazoline as
antimicrobial agents.Imidazolinones have been reported to possess antioxidant
activity.
Moreover Yoneda Naoto et. Al506 have synthesised imidazolinones as
antihypertensive agent. R. C. Dage et. al.507 have synthesised cardiotonic
imidazolones. Armando Rossello et. al. 508 have synthesised imidazolones as
antifungal agent. A. B. Cooper and co-workers509 have found that imidazolones are
inhibitors of farnesyl protein transferase. Machii Daisuke et. al.510 have synthesised
new imidazolones as a telomerase inhibitors and antitumor agents M. R. Jean et. al. 511
have synthesised imidazolones and tested as antileishmanial agent. Chafiq Hamdouchi
et. al. 512 have synthesised imidazolinones and screened for their potent and broad
spectrum activity. M. L. Irene et al.513 have synthesised imidazolinones and tested as
antiretroviral activity (IX). Xu Zhi-Feng et. al. 514 have synthesised imidazolinones as
biological agent. With a view to getting better therapeutic agent, it was contemplated
to synthesized imidazolinones to enhance the overall activity of resulting compounds
which have been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL SCREENING OF 2 [(4'-
CHLOROPHENYL)-6-METHYLIMIDAZO[1,2 -a ]PYRIDIN-3-
YL] METHYLENE - 1" – ARYL - 2" - PHENYL - 5" - OXO-
IMIDAZOLINES.
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SECTION:-I
SYNTHESIS AND BIOLOGICAL SCREENING 2-[(4'-CHLOROPHENYL)-6-
METHYLIMIDAZO [1,2 – a ] PYRIDIN – 3 – YL ] METHYLENE - 1" – ARYL
-2" PHENYL-5"-OXO-IMIDAZOLINES.
Imidazolinones represent one of the most active classes of compounds having
a wide spectrum of biological activities with an aim to getting better therapeutic
agent. The preparations of 2-[(4'-chlorophenyl)-6-methylimidazo[1,2-a]pyridin-3-
yl]methylene-1"-aryl-2"-phenyl-5"-oxo-imidazolines. of Type (XIII) have been
undertaken by the condensation of 4"-{[2-(4'-chlorophenyl)-6-methyl imidazo [1,2-a]


















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I, section-I Page no. 41
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IR SPECTRAL STUDY OF 2-[(4'-CHLOROPHENYL)-6-METHYLIMIDAZO
[1,2- a ] PYRIDIN – 3 - Yl] METHYLENE - 1" - (PHENYL)- 2"-PHENYL -5"-
OXO-IMIDAZOLINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2964 2990-2850 648
C-H str. (sym.) 2860 2880-2860 "
C-H def. (asym.) 1442 1470-1435 "
Alkane
C-H def. (sym.) 1370 1390-1370 "
C-H str. 3057 3090-3030 649
C=C str 1462 1450-1600 "
Aromatic
C-H i.p. (def.) 1219 1300-1100 "
C=O str. 1680 1760-1655 "
C=N str. 1600 1650-1580 "
Imidazole
ring
C=C str. 1500 1540-1480 "
C=N str. 1627 1630-1593 "Imidazo[1,2-a]
pyridine C-N str. 1128 1220-1020 "
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NMR SPECTRAL STUDY OF 2-[(4'-CHLOROPHENYL)-6-
METHYLIMIDAZO [1,2- a ] PYRIDIN – 3 - Yl] METHYLENE - 1" -
(PHENYL)- 2"-PHENYL -5"-OXO-IMIDAZOLINE.








1 2.32 3H singlet Ar-CH3(e)
2 6.52-6.66 2H multiplet Ar-H(d,o)
3 6.99-7.03 2H triplet Ar-H(p,n)
4 7.08-7.26 5H multiplet Ar-H(aa',i,j,k)
5 7.33-7.41 5H multiplet Ar-H(h,l,g,q,m)
6 7.55 3H multiplet Ar-H(bb',c)
7 8.02 1H singlet Ar-H(f)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING 2-[(4'-CHLOROPHENYL)-6-
METHYLIMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE-1"-ARYL-2"-
PHENYL-5"-OXO-IMIDAZOLINES.
(A) synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See(A), Part-I, Section-I (A),on page no. 37
(B) Synthesis of 4"-{[2-(4'-chlorophenyl)-6-methyl imidazo [1,2-a] pyridin-3-
yl] methylene}-2"-phenyl- 5"-oxazolone.
A mixture of benzoylaminoacetic acid (6.0 gm,0.029 mol),acetic
anhydride(4.27 gm,0.032 mol),sodium acetate(2.62 gm,0.032 mol) and 6 – methyl – 2
- ( 4' - chlorolphenyl)imidazo [ 1,2-a ] pyridine – 3 - carboxaldehyde (4.36 gm,0.032
mol) was heated on a waterbath for 4 hrs. Resulting mass poured into ice cold
water,filtered and crystallized from DMF.yield,66%,m.p.143 oC.
(C) Synthesis of 2-[(4'-chlorophenyl)-6-methylimidazo [1,2-a] pyridin-3-yl]
methylene-1"-(phenyl)-2"-phenyl-5"-oxo- imidazolines(13a)
A mixture of phenyl amine (3.0 g, 0.01 mol) and 4"-{[2-(4'-chlorophenyl)-6-
methyl imidazo [1,2-a] pyridin-3-yl] methylene}-2"-phenyl- 5"-oxazolone (4.26 g,
0.01 mol) in dry pyridine (30 ml) was refluxed for 10 hrs. in oil bath. Resulting mass
was poured into crushed ice and neutralised with HCl, filtered and crystallized from
dioxane. Yield 65%, mp. 155ºC.
(C30H21ClN4O ; Required : C, 73.69; H, 4.33; N, 11.46%; found : C, 73.67; H, 4.30;
N, 11.44%)
Similarly other 5-oxo-imidazolines have been prepared. The physicalconstants
are recorded in Table No.13.
(D) Biological Screening of 2-[(4'-chlorophenyl)-6-methylimidazo [1,2-a]
pyridin-3-yl] methylene-1"-aryl-2"-phenyl-5"-oxo- imidazolines.
Biological Screening was carried out as describe in Part-I,Section-I,page
no.38.the zone of inhibition of the test solutions are recorded in graphical chart
No.13
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TABLE CNO. 13 PHYSICAL CONSTANTS OF 2-[(4'-CHLOROPHENYL)-6-METHYLIMIDAZO [1,2- a ] PYRIDIN – 3 - ]
METHYLENE - 1" - (PHENYL)- 2"PHENYL -5"-OXO-IMIDAZOLINES.





13a C6H5- C30H21ClN4O 488.5 155 65 11.46 11.44
13b 3-Cl-C6H4 - C30H20Cl2N4O 523.0 195 61 10.70 10.68
13c 4-Cl-C6H4 - C30H20Cl2N4O 523.0 173 70 10.70 10.68
13d 2-4-(Cl)2-C6H3- C30H19Cl3N4O 557.5 180 75 10.04 10.02
13e 4 -F-C6H4- C30H20ClFN4O 506.5 165 62 11.05 11.03
13f 4-Br-C6H4- C30H20BrClN4O 567.5 190 66 9.87 9.85
13g 4 -OH-C6H4- C30H21ClN4O2 504.5 168 60 11.10 11.08
13h 4-NH2-C6H4- C30H22ClN5O 503.5 166 58 13.90 13.89
13i 4-CH3-C6H4- C31H23ClN4O 502.5 163 55 11.14 11.11
13j 4-OCH3-C6H4- C31H23ClN4O2 518.5 200 69 10.80 10.79
13k 3-NO2-C6H4- C30H20ClN5O3 533.5 182 48 13.12 13.10
13l 4-NO2-C6H4- C30H20ClN5O3 533.5 198 59 13.12 13.10
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GRAPHICAL CHART NO. 13: BIOLOGICAL SCREENING OF 2 - [ ( 4' – CHLOROPHENYL ) – 6 - METHYLIMIDAZO [ 1,2- a ]






















B.mega 14 21 16 18 22 14 15 14 16 21 18 15 22 22 22 0 0
S.aureus 16 20 15 14 19 20 19 22 14 20 15 17 19 23 22 0 0
E.coli 17 19 18 22 21 18 20 21 20 18 17 15 19 22 24 0 0
S. typhi 16 22 18 24 18 15 16 20 17 21 16 16 22 25 23 0 0
A.niger 18 16 21 19 18 20 18 19 18 22 15 12 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-VIII
SECTION – I: BIOLOGICAL SCREENING OF 2-[(4'-CHLOROPHENYL)-6-METHYLIMIDAZO [1,2- a ] PYRIDIN – 3 - ]
METHYLENE - 1" - (ARYL)- 2"-PHENYL -5"-OXO-IMIDAZOLINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
13b-(21) 13b-(20) 13b-(19) 13b-(22) 13c-(21)
13e-(22) 13e-(19) 13d-(22) 13d-(24) 13f-(20)
13j-(21) 13f- (20) 13e- (21) 13h-(20) 13j-(22)
13h-(22) 13h-(21) 13j-(21)
13j-(20) 13i-(20)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
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STUDIES ON MANNICH BASES
INTRODUCTION
Mannich bases containing bridged N-atom exhibit pronounced biological
activities. The study of mannich reaction attracted a great deal of attention to the
chemists because it plays a vital role owing to their wide range of pharmacological
and industrial applications. Mannich bases are also employed as intermediate in
chemical synthesis.515-517 Mannich base derivatives with bridge N-atom have been
found to be potent drug in medicinal science and possess wide range of biological
activities like anticancer, antibacterial, antimalarial, analgesic etc. Mannich bases
have gained important because of their technological applications in polymer
chemistry518, especially as paints and surface. active agents and exhibits complexation
characteristic with many transition metal ions. Over the years there has been much
contraversy about the mechanism of the Mannich reaction. Studies of the reaction
kinetics have led to the following mechanistic proposals.
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SYNTHETIC ASPECT
Different methods have cited in literature to synthesize Mannich bases by
several workers519, 520 using various interesting substractes.
1. P.G. Venkatesha and D. Vanappayya 521 have synthesized aminobenzylated
Mannich bases by the condensation reaction between heterocyclic secondary
amines and benzaldehyde.
2. Seshaiah Krishnan et al522 have synthesized Mannich bases from the schiff bases




















3. Yung-son Hon et al523. have prepared Mannich base from the reaction of phenolic







4. S. N. Pandeya and D. Sriram Dave524 have synthesized Mannich bases by the
condensationofthe acidic group of isatin with formaldehyde and secondary amines.
5. K.W. Chi and co-workers525 have synthesized Mannich base using
1,4,10,13-tetraoxa-7,16 diazacyclooctadecane, formaldehyde and phenolic
derivatives in benzene.
6. A. Christos Kontogiorgis et al.526 have synthesized Mannich base of coumarine
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THERAPEUTIC IMPORTANCE
Mannich bases are associated with a wide variety of biological activities and











T. Lorand and B Kocsis 540 have synthesized some new Mannich ketones and
reported their antibacterial activity. D. D. Erol A.rosen et al.541 have synthesized some
novel mannich base derivatives from 6-acyl-3-(3,5-dimethylpiperidinomethyl)-
2(3H)-benzoxazolones and reported their biological activities. H. M. Hassan542 have
synthesized some new Mannich bases containing 1,8-napthyridine moiety and
reported their antimicrobial activity.
M. Movrin and D. Maysinger 543 have synthesized Mannich bases from
nitroxoline and reported them as biologically active agents. T. Ojanen and
coworkers544 have reported antifungal activity of some mono, bis and quaternary
mannich bases derived from acetophenone. Y. Li, Z. S. Yang et al545have synthesized
some mannich base derivatives and reported their antimalarial activity.
B. Shivarama Holla et al.546 have prepared Mannich bases and tested them
for anthelmintic activity (I) and all the newly synthesized compounds (II) were tested
for their antibacterial and antifungal activity.
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Amodiaquine547,548, Mannich base derivatives (III) which shown an
antimalarial activity superior than chloroquine in areas of high chloroquine resistance.
M. L. Edwards et al.549 have prepared the mannich base of 4-phenyl-3-buten-2-one as
an antiherps agent. K. Malcolm Scott and co-workers550 have prepared the pyrrole
mannich base (IV) as a potent antipsychotic agents.
J. Knoll et al.551 have prepared the mannich base (V) which was the most potent
neuroleptic compound of a series of aryl substituted analogues. Molindone (VI) which
has been reported to demostrate potent neuroleptic activity552. Jan Balzarini and co-
workers553 have prepared the mannich bases of chalcone shows cytotoxic activities.
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H. I. Gul et al554 ,555 have documented antifungal activity of bis mannich bases derived
from acetophenones and some mono mannich bases evaluated for their anticonvulsant
activity. M. S. Shingare et al556 have described the synthesis and the antiviral activity
of mannich bases (VII).
In view of the importance of mannich bases as versatile synthetic intermediates and
the availability of scanty literature on therapeutic properties, we have undertaken the
preparation of mannich bases in following sections.
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF 2 - ( 4' -
CHLOROPHENYL)-6-METHYL- (3-N, N’-DIARYL/DIALKYL
AMINO METHYL)-IMIDAZO [1, 2-a] PYRIDINES.
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2- (4'-
CHLOROPHENYL)-6-METHYL- (3-N, N'-DIARYL/DIALKYL AMINO
METHYL)-IMIDAZO [1, 2-a] PYRIDINES.
In view of getting better therapeutic agent and considering the association of
various biological activity with imidazo[1,2-a]pyridine nucleus, the preparation of
2 -(4'chlorophenyl)-6-methyl- (3-N, N'-diaryl/dialkyl amino methyl)-imidazo [1, 2-a]
pyridines. of Type(XIV) have been synthesised from 6-methyl-2-(4'-













The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I ,page no. 41
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IR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL- (3-N, N'-
DIMETHYL AMINO METHYL)-IMIDAZO [1, 2-a] PYRIDINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
Alkane C-H str.(asym.) 2973 2990-2850 648
C-H str. (sym.) 2881 2880-2860 "
C-H def. (asym.) 1442 1470-1435 "
C-H def. (sym.) 1361 1390-1370 "
C-H str. 3090 3090-3030 649
C=C str 1487 1600-1450 "
Aromatic
C-H i.p. (def.) 1265 1300-1100 "
C-N str. 1174 1220-1020 "Imidazo[1,2-a]
Pyridine C=N str. 1633 1612-1593 "
Halide C-Cl str. 796 800-600 "
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NMR SPECTRAL STUDY OF 2-(4'-CHLOROPHENYL)-6-METHYL- (3-N,
N'-DIMETHYL AMINO METHYL)-IMIDAZO [1, 2-a] PYRIDINE.








1 2.24 6H singlet N-(CH3 )2(i,j)
2 2.36 3H singlet Ar-CH3(g)
3 3.81 2H singlet Ar-H(f)
4 7.05-7.08 1H doublet Ar-H(d)
5 7.40-7.43 2H doublet Ar-H(aa')
6 7.51-7.53 1H doublet Ar-H(c)
7 7.74-7.77 2H doublet Ar-H(bb')
8 8.10 1H singlet Ar-H(e)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-
6-METHYL-(3-N,N'-DIARYL/DIALKYL AMINO METHYL)-IMIDAZO [1, 2-
a] PYRIDINES.
[A] Synthesis of 2-(4'-chlorophenyl)6-methyl imidazo[1,2-a]pyridine
See, Part-I, Section-I,on page no. 37
[B] Synthesis of 2-(4'-chlorophenyl)-6-methyl-(3-N, N'-di methyl
aminomethyl)-imidazo [1, 2-a] pyridines(14a).
A mixture of 2-(4'-chlorophenyl)-6-methyl imidazo[1,2-a]pyridine (2.88 gm,
0.01 mol), formaldehyde (0.3 gm, 0.01 mol) and dimethyl amine (0.87 gm, 0.01 mol)
and HCl in methanol (50 ml) was refluxed for 8 hrs. The product was poured on to
crushed ice. The product was isolated, dried and recrystallised from hexane Yield
65%, m.p. 170oC.
(C17H18ClN3 ; Required : C, 68.11; H, 6.05; N, 14.02%; found : C, 68.10; H, 6.03; N,
14.00%)
Similarly other 2-(4'-chlorophenyl)–6–methyl-(3-N,N'-diaryl/dialkyl
aminomethyl)-imidazo [1, 2-a] pyridines compouns were prepared. The physical
constants are recorded in Table No.14.
[E] Biological screening of 2 - ( 4'- chlorophenyl ) – 6 – methyl - (3-N,N'-
diaryl/dialkylaminomethyl)-imidazo [1, 2-a] pyridines.
Biological screening were carried out as described in Part-I, Section-I,
page no. 38 The zones of inhibition of test solutions are recorded in Graphical Chart
no.14.
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TABLE NO. 14 PHYSICAL CONSTANTS OF 2-(4'CHLOROPHENYL)-6-METHYL-(3-N,N'-DIALKYL/DIARYL AMINO
METHYL)-IMIDAZO [1, 2-a] PYRIDINES.







14a (CH3)2N-(DMA) C17H18ClN3 299.5 170 65 14.02 14.00
14b C4H8NO-(Morpholine) C19H20ClN3 341.5 150 62 12.29 12.26
14c C4H9N2-(Piprazine) C19H21ClN4 340.5 190 69 16.44 16.40
14d (C2H5)2N-(DEthylA) C19H22ClN3 327.5 150 55 12.82 12.81
14e (C6H5)2N-(Diphenyl amine) C27H22ClN3 423.5 210 63 9.91 9.90
14f C4H8N-(Pipiridine) C19H20ClN3 325.5 170 70 12.90 12.88
14g (C2H4Cl)2N-(Bis-2-Chloro) C19H20Cl3N3 396.5 121 62 10.59 10.58
14h (C3H7)2N-(Isopropylamine) C21H26ClN3 355.5 180 69 11.81 11.80
14i C10H13 N2-(N-Phenyl piprazine) C25H25ClN4 416.5 216 62 13.44 13.42
14j C5H11N2-(N-Methyl piprazine) C20H23ClN4 354.5 180 72 15.79 15.76
14k C11H15 N2O –(Benz hyd pip.) C26H27ClN4O 446.5 190 60 12.53 12.51
14l (OHCH2CH2)2N –(Di-ethenol A) C19H20ClN3O 359.5 195 70 11.68 11.65
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GRAPHICAL CHART NO. 14 : BIOLOGICAL SCREENING OF 2 - ( 4' – CHLOROPHENYL ) - 6 - METHYL - ( 3 - N, N'-






















B.mega 17 20 15 19 18 16 14 22 14 21 13 15 22 22 22 0 0
S.aureus 18 18 21 14 20 14 19 18 16 14 22 14 19 23 22 0 0
E.coli 12 21 18 16 22 18 20 19 18 14 16 17 19 22 24 0 0
S. typhi 19 14 17 16 20 16 21 19 16 17 22 15 22 25 23 0 0
A.niger 20 19 21 20 19 11 16 22 19 18 15 14 0 0 0 22
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-IX
SECTION – I: BIOLOGICAL SCREENING OF 2-(4'-CHLOROPHENYL)-6-METHYL-(3-N,N'- DIARYL/DIALKYL AMINO
METHYL)-IMIDAZO [1, 2-a] PYRIDINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
14b-(20) 14b-(18) 14b-(21) 14e-(20) 14c-(21)
14h-(22) 14c-(21) 14f-(18) 14g-(21) 14d-(20)
14j-(21) 14e- (20) 14e-(22) 14k-(22) 14h-(22)
14g-(19) 14g-(20)
14k-(22) 14h-(19)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
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STUDIES ON SCHIFF’S BASES
INTRODUCTION
In recent years, interest has also focused on aza-analogs such as azomethine
derivatives which show a very similar pharmacological profile to classical Over the
past few years, several lead-compounds have been developed.Azomethines are also
known as schiff’s bases and they are well known intermediates for the preparation of
azetidinones, thiazolidinone, formazan, arylacetamide and many other entities of
pharamaceutical potential. These are the compounds containing characteristic –
HC=N– group.
Azomethines are obtained mainly by warming the aldehyde & aromatic
amine togather. Howeve, it is more convenient to work in a solvent such as alcohol,
dilute acetic acid or glacial acetic acid. Some time the reaction is aided by trace of
acid in other cases the hydrochloride of the amines can be used in the synthesis. In
general Schiff’s bases do not react further with either of the reagents used in their
preparation as do most of the other types of simple intermediates.Synthetic Schiff’s
base derivatives contribute in huge libraries owing to their wide applicability in
different fields.
SYNTHETIC ASPECT
Different methods for the preparation of azomethine derivatives documented
in literature are described as under.
1. A. J. Gallant et al.557 have prepared schiff’s bases by condensation of















2. General account of the summary of reaction of aldehydes with amine
(aromatic or aliphatic) has been reviewed by M. S.Murray558.
R-CHO R'-NH2 R-CH=N-R'+
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3. A new one pot procedure for the generation of azomethine has been















4. Strache560 and Van Alphen561 have prepared imine involves in two steps.
a. Add. of the amine to the aldehyde gives aldol. Which are rarely capable of
isolation.
R-CHO R'-NH2+ R-CHOHNHR'
b. The loss of water to give an imine (azomethine), this corresponds to the
“crotonaldehyde stage” of the aldol condensation.
R-CH=N-R' + H2OR-CHO+R'-NH2
5. Oddo and Tognacchini562 have introduced the comparative rates of formation
of Schiff ‘s base from aniline & substituted aniline & aromatic aldehyde
using a cryscopic method follow the course of reaction.
P. L. Beaulieu and co-workers563 have synthesized (E)-N-phenyl methylene
glycine ethyl ester by the cyclocondensation of glycine ethyl ester hydrochloride,









Literature survey reveals that various azomethines have resulted in many









7. Plant harmone activity570
8. Antitubercular571
Smalders et al.572 synthesized some new azomethine as potential antitumor
agents. Sharaf El-Din, and Nabaweyal573 have synthesized some azomethine
derivatives (I) having good antibacterial activity.Chohan et al.574 have synthesized
azomethines, which have been screened and compared for their antibacterial action
















Schiff’s bases exhibit a wide range of pharmacological activities like
antifungal, antibacterial, antiviral, anti-inflammatory etc. R. H. Mehta et al.575 have
synthesized coummarin schiff’s base derivatives (II) and examined for their
antibacterial activity. A. K. Khalafallah and M. E Hassan.576 have prepared some







Chohan et al.577 have synthesized azomethines, which have been screened and
compared for their antibacterial action against bacterial species Escherichia coli,
Pesudomonus aeruginoase and Klebisella pneumoniase. Das Joydip578 have
synthesized trans-N-refinylidene-n-butylamine (III) which found stabillized in
liposomes of phophatidylcholine. The rate of formation of the Schiff’s base is found
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to decrease with increasing cholesteral concentration in the membrane. V. M. Patel 579








M. D. Deshmukh. and A. G. Doshi 580 prepared some new Schiff’s bases show
good antimicrobial activity against test organism S. aureus, E. coli, Saigella
dysenteridse and Salmonella typhi. Wang and Yangang581 have synthesize
diazomethines having plant hormone activity. Das Arima et al.582 have prepared
Schiff’s bases of aminohydroxy guanidine (SB-AHG5) and tested for antiviral activity
against Herpes Simplex virus (HSV-1) and adenovirus (Ad-5) along with 11 other
heterocyclic SB-AHG5.
S. Castellano et. al.583 have prepared azomethine derivatives and evaluated in
vitro against several pathogenic fungi responsible for human disease. B. Shivarama
Holla et. al.584 have documented antibacterial, antifungal and herbicidal activity of
azomethine derivatives.Wang, Yangsng and co-workers585 have screened some
azomethines having good plant homone activity. Pascal Rotheist et. al.586have
reported soe new azomethines as antiparasitic agents.
B. Shivarama Holla., et al.587 have synthesized azomethines having
antibacterial and anti-inflammatory activity. J. R. Dimmoch et. al.588 have reported
azomethines as cytotoxic agents.Adnan A. et. al.589 have synthesised azomethines
possessing significant antibacterial and antifungal activity.
C. Alexandru et al.590 have synthesized azomethines, which have good
analgesic and antipyretic properties. S. N. Pandeya et al.591 have synthesized Schiff
bases showed good activity against Vibrio cholerae non-o., Shigella boydii,
Enterococcus faecalis and Edwaredsiella torla with MIC in the rang of 10-25 μg/ml.
Some compounds were found to be active against Salmonellal typhi and Vibro
cholerae-0, (MIC 25-150 μg/ml).
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R. V. Chambhare et al.592 have prepared some azomethines and tested for their
antimicrobial activity. B. Shivarama Holla et. al.593 have synthesized azomethines of























R, Tilak et al.594 have synthesized some Schiff’s bases, thiazolidinones 4-
triazolines, and formazones of 2-chloro phenothiazines and screened against
carrageenininduced edema in albino rats. The thiazolidinones showed promising anti-
inflammatory activity.
Looking to the interesting properties of azomethines, we have synthesized
some new azomethines, which have been described as under.
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF 2-[(4'-
CHLOROPHENYL )-6-METHYL IMIDAZO [1, 2- a ] PYRIDIN
– 3 - YL] METHYLENE ARYLAMINES.
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-[(4'-
CHLOROPHENYL )-6-METHYL IMIDAZO [1, 2- a ] PYRIDIN – 3 - YL]
METHYLENEARYLAMINES.
Looking to the interesting properties of azomethines, with an intension
tosynthesising better therapeutic agents, azomethine derivatives of Type (XV) have
been synthesized by the condensation of 6-methyl-2-(4'-methylphenyl)imidazo[1,2-
















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC,
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I page no. 41
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IR SPECTRAL STUDY OF 2-[(4'-CHLOROPHENYL )-6-METHYL
IMIDAZO [1, 2- a ] PYRIDIN – 3 - YL] METHYLENE (4'''-
CHLOROPHENYL)AMINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2910 2990-2850 648
C-H str. (sym.) 2860 2880-2860 "
C-H def. (asym). 1454 1470-1435 "
Alkane
C-H def. (sym.) 1396 1390-1370 "
C-H str. 3033 3090-3030 649
C=C str 1483 1600-1450 "
Aromatic
C-H i.p. (def.) 1300 1300-1100 "
C-N str 1049 1220-1020 "Schiff base
C=N str 1705 1710-1650 "
C-N str. 1080 1220-1020 "Imidazo[1,2-a]
pyridine C=N str. 1694 1612-1593 "
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NMR SPECTRAL STUDY OF 2-[(4'-CHLOROPHENYL )-6-METHYL
IMIDAZO [1, 2- a ] PYRIDIN – 3 - YL] METHYLENE (4'''-
CHLOROPHENYL)AMINE.








1 2.35 3H singlet Ar-(CH3 )(i)
2 6.93-6.96 1H singlet Ar-H(f)
3 7.06 2H singlet Ar-H(dd')
4 7.18-7.27 4H doublet Ar-H(aa',cc')
5 7.39-7.41 2H doublet Ar-H(bb')
6 7.45-7.48 2H doublet Ar-H(e,h)
7 8.11 1H doublet Ar-H(g)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-[(4'-CHLOROPHENYL)
-6-METHYL IMIDAZO [1, 2- a ] PYRIDIN – 3 - YL] METHYLENE
ARYLAMINES.
[A] Synthesis of -2-(4'-chlorophenyl)6-methyl imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 2-(4'-chlorolphenyl)-6-methyl imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-[(4'-chlorophenyl )-6-methyl imidazo [1, 2- a ]
pyridin – 3- yl] methylene-(4"'-Chlorophenyl)amines(15c)
A mixture of 2-(4'-chlorophenyl) 6-methyl imidazo[1,2-a]pyridine-3-
carboxaldehyde (2.28gm, 0.01 mol) and p-Chloroaniline (1.08 gm, 0.01 mol) in
toluene (20 ml) in presence of catalytic amount of glacial acetic acid was refluxed for
6 hr. The contents were cooled and poured in crushed ice product was isolated
crystallized from methanol. Yield, 76%, m.p. 195oC,
(C21H15Cl2N3 ; Required : C, 66.33; H, 3.98; N, 11.05%; found : C, 66.30; H, 3.95; N,
11.04%)
Similarly, other2-[(4'-chlorophenyl )-6-methyl imidazo [1, 2- a ] pyridin – 3 -
yl] methylene arylamines were prepared. The physical constants are recorded in Table
No. 15.
[D] Biological Screening 2-[(4'-chlorophenyl )-6-methyl imidazo [1, 2- a ]
pyridin – 3 - yl] methylene arylamines
Biological Screening was carried out as described in Part-I , Section-I ,Page
no.38 The zone of inhibition of the test solution are recorded in Graphical Chart No.
15
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TABLE NO. 15 PHYSICALCONSTANTS OF 2- [(4'-CHLOROPHENYL )-6-METHYL IMIDAZO [1, 2- a ] PYRIDIN – 3 - YL]
METHYLENE (ARYL) AMINES.







15a C6H5- C21H16ClN3 345.5 155 62 12.15 12.13
15b 3-Cl-C6H4- C21H15Cl2N3 380.0 160 66 11.05 11.02
15c 4-Cl-C6H4- C21H15Cl2N3 380.0 195 76 11.05 11.02
15d 2-4-(Cl)2-C6H3- C21H14Cl3N3 414.5 138 75 10.13 10.10
15e 2 -F-C6H4- C21H15ClFN3 363.5 180 50 11.55 11.52
15f 4 -F-C6H4- C21H15ClFN3 363.5 121 60 11.55 11.52
15g 4-CH3-C6H4- C22H18ClN3 359.5 193 55 11.68 11.65
15h 4-OCH3-C6H4- C22H18ClN3O 375.5 136 59 17.18 17.16
15i 4-6-(OCH3)2 - C4 N2- C21H18ClN5O2 407.5 170 60 17.17 17.15
15j 3-NO2-C6H4- C21H15ClN4O2 390.5 215 65 14.34 14.32
15k 4-NO2-C6H4- C21H15ClN4O2 390.5 216 66 14.34 14.32
15l 5-CH3-C5H3N- C21H17ClN4 360.5 175 50 15.53 15.51
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GRAPHICAL CHART NO. 15 : BIOLOGICAL SCREENING OF 2 -[ ( 4' - CHLOROPHENYL ) -6 - METHYL IMIDAZO [1, 2- a ]
PYRIDIN – 3 - YL] METHYLENE( ARYL)AMINES.
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-X
SECTION – I : BIOLOGICAL SCREENING OF 2-[(4'-CHLOROPHENYL )-6-METHYL IMIDAZO [1, 2- a ] PYRIDIN – 3 - YL]
METHYLENE (ARYL)AMINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A. niger
15b-(20) 15b-(18) 15b-(21) 15e-(20) 15c-(21)
15h(22) 15c-(21) 15c-(18) 15g-(21) 15d-(20)
15j-(21) 15e-(20) 15e-(22) 15k-(22) 15f- (22)
15g-(19) 15g-(20)
15j-(20) 15h-(19)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
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STUDIES ON BENZODIAZEPINES .
INTRODUCTION
Benzodiazepines are characterized by their possession of fused benzene ring
with seven membered heterocyclic ring containing amino group at five position and
nitrogen, sulphur or oxygen at one position with double bond in between forth carbon
and fifth nitrogen atom.
x
N
( I ) X = NH,S,O
1,5-Benzodiazepines viz. benzodiazepine, benzothiazepines and
benzoxazepines are very important compounds because of their pharmacological
properties. Some of the popular drugs based on these compounds are Thiazesim,
Diltiazem595 and Clentienzem596etc.
Many pharmacological compositions of benzodiazepines have been
patented.597-600
SYNTHETIC ASPECT
The literature survey revealed that the most explored route for the synthesis of
1,5-benzodiazepines is the reaction either of o-phenylene diamine with 1,3-
disubstituted-2-propen-1-ones (chalcone). 1,5-Benzodiazepines are also synthesized
by cyclocondensation of the corresponding 2-substitutted anilines with suitable
enones or 1,3 or (α, β-dicarbonyl compounds.
Different methods for preparation of 1, 5-benzodiazepines are reportd in
literature as under.
Methods for the preparation of 1,5-benzodiazepines are as under.
1. By the condensation of o-phenylenediamine with α, β-unsaturated carbonyl 
compounds.601-603
2. By the condensation of o-phenylenediamine with  α-haloketones.604
3. By the condensation of o-phenylenediamine with ketones in the presence of
polyphosphoric acid, silica gel605, MgO and POCl3.606













































X= NH, S, O
The mechanism includes the attack of lone pair of electron of nitrogen atom of
2-substituted aniline (b) on keto-enol form of 1,3-disubstituted-2-propen-1-ones (a)
affords hydrated product (c) which on dehydration yields intermediate product (d).
Intermediate (d), on intramolecular cyclization yield dihydro intermediate (e) in the
presence of acid. (e) On tautomerises to the final product (f).
MEDICINAL INTEREST
Considerable research has been undertaken to extend the activity and reduce
toxicity of benzodiazepines . The specific biological activities to Benzoheterozepines
have been summarized as under.
1. Central nervous stimulating agent 607, 608
2. Tranquilizer609
3. Antidepressant610
4. Antitumor activity611, 612
5. Antimicrobial activity613, 614
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A. Bauer et. al.621 have synthesized 4-amino-1,5-benzodiazepines having
psychotropic activity. R. G. Smith et. al.622 have synthesized pyrazino
benzodiazepines possessing anxiolytic activity. G.B. De Sarro et. al.,623 have
synthesized 1,5-benzodiazepines (I) derivatives possessing anticonvulsant activity.
H.F. Miranda et.al.624 has reported antinociceptive action benzodiazepines. H. Yamaji

















( I ) ( II )
A. Farese et. al. 626 have synthesized benzodiazepines and evaluated their
biological activities by luciferase transactivation and anti-viral assay. De S.
Giovambattista et. al.627 have synthesized 1,4-benzodiazepine derivatives as
anticonvulsant agents. S. E. Ellen 628 has prepared 1,5-benzodiazepines (III) having
cholecystokininantagonistic or agonistic activity.













K.A. Rao et. al.629 have synthesized 1,4-benzodiazepines as DNA-interactive
antitumor antibiotics. L. Wang et. al.630 have synthesized benzodiazepine derivatives
as CDK5 inhibitors. R. Kumar et. al.631 have synthesized 3H-1,5-benzodiazepine
derivatives and screened for anthelmintic activities. S. Joseph et. al.632 have reported
benzodiazepines that activates cardiac slow delayed rectifier K+ currents.
T. Nagao et.al.633 have synthesized 1,5-benzothiazepine derivatives and tested
their coronary vasodilating effect. K.S. Atwal et. al.634 have synthesized 1,5-
benzothiazepines (IV) ,which are calcium channel blockers. V. Ambrogi et. al.635 have






X=S, R1=H, R=Substituted phenyl
( IV )
C. Saturnino et. al. 636 have synthesized 1,5-benzothiazepines and examined
in vitro for their calcium antagonist activity compared to the diltiazem. S. Koichi et.
al.637 have prepared benzodiazepines, benzothiazepines and benzoxazepines
compounds (V),(VI) of potentiating retinoid.

















R1-R3R5R6=H; R4=H, OH,NO2, X=NH,S
Y = O( V ) ( VI )
C. Sanchez-Mateo et. al. 638 have studied neuropharmacological activity of
hetero[2,1] benzothiazepines. F. L. Ansari et. al.639 have synthesized 1,5-
benzothiazepine derivatives and studied their urease and  α-glucosidase inhibitors
properties. N. Rastkari et. al.640 have synthesized benzothiazepine derivatives (VII)








L.R.Swettt et. al. 641 have reported anti-inflammatory activity of 4,5-dihydro
benzoxazepine derivatives. D. M. Zisterer et al642 have reported pyrrolo-1,5-
benzoxazepines as a new class of apoptotic agents.
P. B. Bharucha and H. B. Naik643 have prepared 1,4-oxazipine derivatives and
studied their antimicrobial activity. M. Takashi et. al. 644 have synthesized 4,1-
benzoxazepine (VII) derivatives with potent squalene synthase inhibitory activities.











Shalaby and Alyaa A.645 has synthesized pyrrolo-1,5-benzoxazepine-6
derivatives (IX) and reported as microtubule-targeting agent, in both STl-5H-








Younes Laras et. al.646 have prepared various substituted 4,5-dihydro-3H-
spiro [1,5]-benzoxazepine-2,4’-piperidine and assayed as the possible aspartyl
protease inhibitors HIV Protease (HIV-1) and B-Secretase (BACF-1).
B. Basavaraju et al647 have synthesized methylquinolono[3,2-b][1,5]
benzodiazepine (X) and methylquinolono[3,2-b][1,5] benzoxazepine (XI) and its










( X ) ( XI )
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In light of wide varieties of biological activities exhibited by 1,5-benzoheterozepines
it appeared of interest to synthesize 1,5-benzoheterozepines derivatives, in order to
achieving compounds having better therapeutic activity described as under.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF-4"-ARYL-
2"-YL-[2-(4'-CHLOROPHENYL -6-METHYL IMIDAZO [1, 2-a]
PYRIDIN]-1"H,-1",5" BENZODIAZEPINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL SCREENING OF 4"-ARYL-2"-YL-[2-(4'-
CHLOROPHENYL -6-METHYL IMIDAZO [1, 2-a] PYRIDIN]-1"H,-1",5"
BENZODIAZEPINES
Benzodiazepines have been reported to various pharmacological activities like
therapeutic activities, like anthelmintic ,anticonvulsant, antimicrobial etc. . In order
to achieving better drug potency, we have prepared benzodiazepines derivatives of
4"-aryl-2"-yl-[2-(4'-chlorophenyl -6-methyl imidazo [1, 2-a] pyridin]-1"-H,-1",5"
benzodiazepines. Type (XVI) by the cyclocondensation of 2-(4'-chlorophenyl)-6-
methyl-3-[1"-aryl- 2"-propene1"-one-3-yl ]-imidazo[1,2-a]pyridine of Type (I) with


















The constitution of the synthesized compounds have been characterized by
using elemental analyses, infrared,1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy and TLC.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 50 µg/ml. The
biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in part-I,section-I , Page no. 41
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IR SPECTRAL STUDY OF 4"-(4'''-METHYLPHENYL)-2"-YL-[2-(4'-
CHLOROPHENYL -6 – METHYL IMIDAZO [1, 2-a] PYRIDIN]-1"H,-1",5"
BENZODIAZEPINE.
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc).
Frequency in cm-1Type Vibretion
mode Observd Reported
Ref.
C-H str.(asym.) 2935 2990-2850 648
C-H str. (sym.) 2873 2880-2860 "
C-H def. (asym. 1440 1470-1435 "
Alkane
C-H def. (sym.) 1375 1390-1370 "
C-H str. 3041 3090-3030 649
C=C str 1517 1600-1450 "
Aromatic
C-H i.p. (def.) 1170 1300-1100 "
C-N str 1076 1220-1020 "
C=N str 1693 1710-1650 "
Benzdiazipine
N-H str. 3350 3350-3250 "
C-N str. 1087 1220-1020 "Imidazo[1,2-a]
pyridine C=N str. 1604 1612-1593 "
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NMR SPECTRAL STUDY OF 4"-(4'''-METHYLPHENYL)-2"-YL-[2-(4'-
CHLOROPHENYL -6 – METHYL IMIDAZO [1, 2-a] PYRIDIN]-1"H,-1",5"
BENZODIAZEPINE.









1 2.35 3H singlet Ar-CH3(n)
2 2.39 3H singlet Ar-CH3(m)
3 4.50 1H singlet Ar-H(h)
4 6.40 2H singlet Ar-H(i,k)
5 6.70-6.89 5H multiplate Ar-H(cc’,j.l,f)
6 7.09-7.014 2H doublet Ar-H(aa')
7 7.21-7.39 3H doublet Ar-H(bb',e)
8 7.62-7.64 2H doublet Ar-H(dd’)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF -4"-ARYL-2"-YL-[2-(4'-
CHLOROPHENYL -6-METHYL IMIDAZO [1, 2-a] PYRIDIN]-1"H,-1",5"
BENZODIAZEPINES.
[A] Synthesis of 6-methyl-2-(4'-chlorophenyl)imidazo[1,2-a]pyridine
See, Part-I, Section-I ,on page no. 37
[B] Synthesis of 6-methyl-2-(4'-chlorolphenyl)imidazo[1,2-a]pyridine-3-
carboxaldehyde
See, Part-I, Section-I , on page no. 37
[C] Synthesis of 2-(4'-chlorophenyl)-6-methyl- 3-[1"-(4"'-methylphenyl)-
2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine.
See, Part-I, Section-I ,on page no. 37
[D] Synthesis of -4"-(4"'methylphenyl)-2"-yl-[2-(4'-chlorophenyl -6-methyl
imidazo [1, 2-a]pyridin]-1"H,-1",5" benzodiazepines(16i).
A Mixture of solution of 2-(4'-chlorophenyl)-6-methyl-3-[1"-(4"'-
methylphenyl)- 2"-propene-1"-one-3-yl ]-imidazo [1,2-a]pyridine (2.74 gm, 0.01 mol)
and O-phenylene diamine (1.10gm, 0.01 mol) in toluene (20 ml)and sulphuric acid
was heated under reflux for 12 hrs. on oilbath . The excess solvent was distilled out
than reaction mixture was cooled and poured on to crushed ice. where upon a solid
separated out, which was filtered and crystallized from ethanol. Yield 70%,
m.p.175oC
(C30H23ClN4 ; Required : C, 75.86; H, 4.88; N, 11.80%; found C, 75.85; H, 4.87; N,
11.78%;)
Similarly, other-4"-aryl-2"-yl-[2-(4'-chlorophenyl -6-methyl imidazo [1, 2-
a]pyridin]-1"H,-1",5" benzodiazepines were prepared. The physical data are recorded
in Table No.16
[E] Biological Screening of-4"-aryl-2"-yl-[2-(4'-chlorophenyl -6-methyl
imidazo [1, 2-a]pyridin]-1"H,-1",5" benzodiazepines.
Biological Screening were carried out as described in Part-I , Section-1,Page
no. 38 The zones of inhabition of test solution are recorded in Graphical Chart No 16.
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TABLE NO. 16 PHYSICAL COSTANTS OF -4"-(ARYL)-2"-YL-[2-(4'-CHLOROPHENYL -6 – METHYL IMIDAZO [1, 2-a]
PYRIDIN]-1"H,-1",5"- BENZODIAZEPINES.





16a C6H5- C29H21ClN4 460.5 199 69 12.15 12.13
16b 3-Cl-C6H4 - C29H20Cl2N4 495.0 210 56 11.31 11.30
16c 4-Cl-C6H4 - C29H20Cl2N4 495.0 170 67 11.31 11.31
16d 2-4-(Cl)2-C6H3- C29H19Cl3N4 529.5 180 55 10.57 10.56
16e 4 -F-C6H4- C29H20ClFN4 478.5 230 73 11.70 11.68
16f 4-Br-C6H4- C29H20BrClN4 539.5 198 59 10.38 10.35
16g 4 -OH-C6H4- C29H21ClN4O 476.5 185 67 11.75 11.73
16h 4-NH2-C6H4- C29H22ClN5 475.5 195 60 14.71 14.70
16i 4-CH3-C6H4- C30H23ClN4 474.5 175 70 11.80 11.78
16j 4-OCH3-C6H4- C30H23ClN4O 490.5 200 55 11.41 11.40
16k 3-NO2-C6H4- C29H20ClN5O2 505.5 167 49 13.84 13.82
16l 4-NO2-C6H4- C29H20ClN5O2 505.5 188 50 13.84 13.83
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GRAPHICAL CHART NO.16: BIOLOGICAL SCREENING OF -4"-(ARYL)-2"-YL-[2-(4'-CHLOROPHENYL -6 – METHYL
IMIDAZO [1, 2-a] PYRIDIN]-1"H,-1",5"- BENZODIAZEPINES.
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COMPARATIVE BIOLOGICAL SCREENING STUDY WITH KNOWN STANDARD DRUGS
PART-XI
SECTION – I : BIOLOGICAL SCREENING OF 4"-ARYL-2"-YL-[2-(4'-CHLOROPHENYL -6 – METHYL IMIDAZO [1, 2-a]
PYRIDIN]-1"H,-1",5" BENZODIAZEPINES.
Antibacterial activity Antifungal activity
Zone of inhibition in m. m. Zone of inhibition in m. m.
B. mega S. aureus E-coli S. typhi A.
Niger
16b-(22) 16d-(20) 16a-(21) 16b-(22) 16a-(21)
16g(21) 16f-(22) 16b-(20) 16e-(24) 16c-(20)
16j-(21) 16g-(22) 16c-(20) 16i- (22) 16i-(22)
16i- (23) 16d-(24) 16k-(21)
15l-(21) 16l-(23)
Ampicillin (50 µg) 22 19 19 22 --
Chloramphenicol(50 µg) 22 23 22 25 --
Norfloxacin (50 µg) 22 22 24 23 --
Greseofulvin (50 µg) -- -- -- -- 22
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